Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Busulfan | 90 | 2024 | 776 | 15.270 |
Why?
|
Transplantation Conditioning | 86 | 2023 | 2310 | 7.870 |
Why?
|
Hematopoietic Stem Cell Transplantation | 130 | 2024 | 6690 | 6.560 |
Why?
|
Vidarabine | 42 | 2024 | 1353 | 6.120 |
Why?
|
Antineoplastic Agents, Alkylating | 22 | 2019 | 594 | 4.480 |
Why?
|
Graft vs Host Disease | 77 | 2024 | 2756 | 3.590 |
Why?
|
Leukemia, Myeloid, Acute | 59 | 2024 | 6953 | 3.530 |
Why?
|
Adenine Nucleotides | 15 | 2016 | 351 | 3.170 |
Why?
|
Transplantation, Homologous | 90 | 2021 | 2933 | 3.140 |
Why?
|
Arabinonucleosides | 12 | 2016 | 438 | 2.850 |
Why?
|
Cyclophosphamide | 51 | 2024 | 3098 | 2.790 |
Why?
|
Melphalan | 26 | 2023 | 836 | 2.590 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 71 | 2024 | 15995 | 2.330 |
Why?
|
Myeloablative Agonists | 18 | 2023 | 389 | 2.190 |
Why?
|
Drug Synergism | 16 | 2024 | 1325 | 2.110 |
Why?
|
Bone Marrow Transplantation | 61 | 2024 | 1658 | 1.940 |
Why?
|
Hematologic Neoplasms | 25 | 2023 | 1914 | 1.860 |
Why?
|
Myelodysplastic Syndromes | 27 | 2021 | 3027 | 1.730 |
Why?
|
Deoxycytidine | 12 | 2020 | 1367 | 1.710 |
Why?
|
Lymphoma | 17 | 2017 | 1479 | 1.660 |
Why?
|
Histone Deacetylase Inhibitors | 4 | 2024 | 618 | 1.640 |
Why?
|
Hodgkin Disease | 15 | 2022 | 1449 | 1.520 |
Why?
|
Stem Cell Transplantation | 19 | 2020 | 1374 | 1.510 |
Why?
|
Immunosuppressive Agents | 27 | 2017 | 1433 | 1.440 |
Why?
|
Depsipeptides | 4 | 2023 | 78 | 1.390 |
Why?
|
Hydroxamic Acids | 7 | 2016 | 447 | 1.380 |
Why?
|
Drug Monitoring | 7 | 2019 | 336 | 1.280 |
Why?
|
Cladribine | 5 | 2024 | 234 | 1.240 |
Why?
|
Epigenesis, Genetic | 4 | 2016 | 1407 | 1.220 |
Why?
|
Humans | 360 | 2024 | 264777 | 1.200 |
Why?
|
Thalassemia | 4 | 2022 | 26 | 1.170 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 28 | 2016 | 2559 | 1.150 |
Why?
|
Leukemia, Myeloid | 19 | 2010 | 967 | 1.150 |
Why?
|
DNA Damage | 14 | 2022 | 1964 | 1.150 |
Why?
|
Azacitidine | 6 | 2024 | 1162 | 1.090 |
Why?
|
Apoptosis | 17 | 2024 | 7720 | 1.080 |
Why?
|
Hepatic Veno-Occlusive Disease | 4 | 2020 | 123 | 1.040 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 6 | 2016 | 219 | 1.030 |
Why?
|
Adult | 210 | 2023 | 78851 | 0.980 |
Why?
|
Middle Aged | 210 | 2023 | 87361 | 0.970 |
Why?
|
Multiple Myeloma | 13 | 2020 | 2182 | 0.970 |
Why?
|
Antineoplastic Agents | 27 | 2022 | 14417 | 0.970 |
Why?
|
Poly(ADP-ribose) Polymerase Inhibitors | 3 | 2024 | 487 | 0.960 |
Why?
|
Cell Line, Tumor | 22 | 2024 | 14643 | 0.960 |
Why?
|
Drug Interactions | 5 | 2018 | 566 | 0.950 |
Why?
|
Survival Analysis | 46 | 2021 | 9276 | 0.930 |
Why?
|
Male | 234 | 2023 | 124561 | 0.910 |
Why?
|
Sulfonamides | 5 | 2024 | 1848 | 0.880 |
Why?
|
Cystitis | 3 | 2021 | 108 | 0.860 |
Why?
|
Cell Survival | 23 | 2017 | 3060 | 0.850 |
Why?
|
Alkylating Agents | 2 | 2022 | 78 | 0.840 |
Why?
|
Lymphoma, T-Cell | 2 | 2015 | 363 | 0.830 |
Why?
|
Drug Resistance, Neoplasm | 11 | 2016 | 5218 | 0.810 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 12 | 2020 | 2806 | 0.810 |
Why?
|
Drug Combinations | 4 | 2024 | 628 | 0.790 |
Why?
|
Virus Activation | 3 | 2019 | 231 | 0.770 |
Why?
|
DNA Repair | 7 | 2022 | 1881 | 0.760 |
Why?
|
Adolescent | 95 | 2021 | 31537 | 0.750 |
Why?
|
Female | 216 | 2023 | 143788 | 0.740 |
Why?
|
DNA, Viral | 4 | 2018 | 678 | 0.700 |
Why?
|
Transplantation, Autologous | 30 | 2023 | 1961 | 0.690 |
Why?
|
Immunotherapy, Adoptive | 6 | 2023 | 1792 | 0.690 |
Why?
|
Plasma | 1 | 2020 | 159 | 0.670 |
Why?
|
HLA Antigens | 4 | 2017 | 575 | 0.670 |
Why?
|
Reactive Oxygen Species | 3 | 2022 | 999 | 0.650 |
Why?
|
Endoplasmic Reticulum Stress | 1 | 2020 | 200 | 0.630 |
Why?
|
Leukemia | 37 | 2010 | 1653 | 0.620 |
Why?
|
Cytomegalovirus Infections | 5 | 2019 | 458 | 0.620 |
Why?
|
Antigens, Neoplasm | 2 | 2023 | 1528 | 0.590 |
Why?
|
Fluoresceins | 1 | 2017 | 73 | 0.590 |
Why?
|
Wiskott-Aldrich Syndrome | 1 | 2017 | 24 | 0.590 |
Why?
|
Membrane Potential, Mitochondrial | 4 | 2020 | 133 | 0.590 |
Why?
|
Graft Survival | 19 | 2016 | 1092 | 0.580 |
Why?
|
Infusions, Intravenous | 13 | 2012 | 1401 | 0.570 |
Why?
|
fms-Like Tyrosine Kinase 3 | 4 | 2018 | 809 | 0.570 |
Why?
|
BK Virus | 4 | 2020 | 124 | 0.570 |
Why?
|
Cell Proliferation | 5 | 2017 | 7257 | 0.570 |
Why?
|
Allografts | 13 | 2018 | 656 | 0.570 |
Why?
|
Signal Transduction | 9 | 2020 | 12084 | 0.570 |
Why?
|
Recurrence | 41 | 2023 | 4835 | 0.570 |
Why?
|
Polyomavirus Infections | 4 | 2020 | 139 | 0.560 |
Why?
|
Young Adult | 28 | 2021 | 21570 | 0.560 |
Why?
|
Metoprolol | 4 | 2003 | 28 | 0.560 |
Why?
|
Tumor Virus Infections | 4 | 2020 | 225 | 0.550 |
Why?
|
Transplantation, Haploidentical | 2 | 2022 | 142 | 0.550 |
Why?
|
beta-Thalassemia | 1 | 2016 | 17 | 0.550 |
Why?
|
Aged | 112 | 2023 | 71044 | 0.550 |
Why?
|
Immunity, Cellular | 4 | 2017 | 428 | 0.550 |
Why?
|
Bridged Bicyclo Compounds, Heterocyclic | 4 | 2024 | 934 | 0.540 |
Why?
|
Hemorrhage | 3 | 2017 | 719 | 0.540 |
Why?
|
Survival Rate | 44 | 2019 | 12311 | 0.530 |
Why?
|
Pharmacogenetics | 2 | 2017 | 256 | 0.530 |
Why?
|
Disease-Free Survival | 38 | 2018 | 10063 | 0.530 |
Why?
|
Dose-Response Relationship, Drug | 20 | 2018 | 5006 | 0.520 |
Why?
|
Phosphoramide Mustards | 5 | 2002 | 37 | 0.510 |
Why?
|
Virus Diseases | 2 | 2018 | 403 | 0.500 |
Why?
|
Neoplasms, Second Primary | 3 | 2022 | 1359 | 0.500 |
Why?
|
Killer Cells, Natural | 4 | 2019 | 916 | 0.500 |
Why?
|
Child | 37 | 2022 | 29371 | 0.500 |
Why?
|
Bortezomib | 2 | 2016 | 546 | 0.500 |
Why?
|
Flow Cytometry | 8 | 2017 | 3061 | 0.490 |
Why?
|
Myocardium | 7 | 1999 | 1312 | 0.490 |
Why?
|
Thiotepa | 11 | 2024 | 122 | 0.490 |
Why?
|
Tumor Cells, Cultured | 19 | 2017 | 5512 | 0.480 |
Why?
|
T-Lymphocytes | 18 | 2022 | 3918 | 0.470 |
Why?
|
Chimerism | 1 | 2014 | 65 | 0.470 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 6 | 2023 | 1674 | 0.470 |
Why?
|
Nervous System Diseases | 1 | 2018 | 503 | 0.470 |
Why?
|
Follow-Up Studies | 38 | 2019 | 15012 | 0.460 |
Why?
|
Heart Transplantation | 6 | 2016 | 893 | 0.460 |
Why?
|
Indoles | 2 | 2016 | 1018 | 0.460 |
Why?
|
Salvage Therapy | 9 | 2018 | 2079 | 0.460 |
Why?
|
Treatment Outcome | 61 | 2021 | 33286 | 0.450 |
Why?
|
Remission Induction | 27 | 2020 | 3621 | 0.440 |
Why?
|
Drug Screening Assays, Antitumor | 5 | 2020 | 567 | 0.430 |
Why?
|
Niacinamide | 1 | 2014 | 421 | 0.430 |
Why?
|
Prognosis | 44 | 2020 | 21878 | 0.430 |
Why?
|
Daunorubicin | 11 | 2016 | 304 | 0.420 |
Why?
|
Histocompatibility Testing | 11 | 2018 | 475 | 0.420 |
Why?
|
Microbiota | 1 | 2018 | 547 | 0.410 |
Why?
|
Crowns | 2 | 2001 | 4 | 0.410 |
Why?
|
Aluminum Oxide | 2 | 2001 | 12 | 0.410 |
Why?
|
Bayes Theorem | 4 | 2022 | 1043 | 0.400 |
Why?
|
DNA Methylation | 3 | 2018 | 2699 | 0.400 |
Why?
|
Lymphoma, Non-Hodgkin | 14 | 2010 | 1049 | 0.400 |
Why?
|
Drug Administration Schedule | 16 | 2015 | 3506 | 0.400 |
Why?
|
Neoplasms | 11 | 2023 | 15348 | 0.400 |
Why?
|
Neoplasm Proteins | 3 | 2020 | 3279 | 0.390 |
Why?
|
Amsacrine | 11 | 1990 | 62 | 0.390 |
Why?
|
Neoplasm Recurrence, Local | 11 | 2023 | 10128 | 0.380 |
Why?
|
Etoposide | 15 | 2018 | 876 | 0.380 |
Why?
|
Phenylurea Compounds | 1 | 2014 | 589 | 0.380 |
Why?
|
Area Under Curve | 6 | 2020 | 719 | 0.370 |
Why?
|
Injections, Intravenous | 10 | 2011 | 576 | 0.370 |
Why?
|
Metronidazole | 1 | 2011 | 152 | 0.370 |
Why?
|
Everolimus | 4 | 2017 | 415 | 0.370 |
Why?
|
Calcineurin Inhibitors | 3 | 2016 | 72 | 0.370 |
Why?
|
Adrenergic beta-Antagonists | 3 | 2003 | 330 | 0.370 |
Why?
|
Heart Failure | 10 | 2014 | 2544 | 0.370 |
Why?
|
Gene Expression Regulation, Leukemic | 2 | 2016 | 568 | 0.370 |
Why?
|
Acute Disease | 26 | 2018 | 2458 | 0.360 |
Why?
|
Cross-Linking Reagents | 1 | 2010 | 154 | 0.350 |
Why?
|
Hematopoietic Stem Cells | 14 | 2015 | 1268 | 0.350 |
Why?
|
Administration, Oral | 8 | 2020 | 1566 | 0.350 |
Why?
|
Aldehyde Dehydrogenase | 3 | 2002 | 105 | 0.350 |
Why?
|
Lymphocyte Depletion | 6 | 2018 | 270 | 0.350 |
Why?
|
Cord Blood Stem Cell Transplantation | 4 | 2016 | 366 | 0.350 |
Why?
|
Genes, cdc | 1 | 2009 | 81 | 0.350 |
Why?
|
Cytarabine | 18 | 2018 | 1980 | 0.340 |
Why?
|
Retrospective Studies | 50 | 2024 | 38324 | 0.340 |
Why?
|
Cardiomyopathy, Dilated | 3 | 2003 | 239 | 0.340 |
Why?
|
Prospective Studies | 23 | 2024 | 13011 | 0.340 |
Why?
|
Drug Therapy, Combination | 15 | 2015 | 2343 | 0.340 |
Why?
|
Tumor Suppressor Proteins | 3 | 2014 | 1863 | 0.340 |
Why?
|
Antilymphocyte Serum | 9 | 2013 | 232 | 0.340 |
Why?
|
Whole-Body Irradiation | 9 | 2016 | 315 | 0.330 |
Why?
|
Chromatography, High Pressure Liquid | 5 | 1997 | 568 | 0.330 |
Why?
|
Hematologic Diseases | 4 | 2020 | 243 | 0.330 |
Why?
|
Lymphoproliferative Disorders | 2 | 2010 | 371 | 0.320 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2023 | 1155 | 0.310 |
Why?
|
Child, Preschool | 21 | 2020 | 16350 | 0.310 |
Why?
|
Phthalazines | 2 | 2022 | 253 | 0.310 |
Why?
|
Sequence Analysis, DNA | 8 | 2016 | 2493 | 0.310 |
Why?
|
Nucleosides | 2 | 2022 | 61 | 0.300 |
Why?
|
Genomic Library | 3 | 1998 | 41 | 0.300 |
Why?
|
Tacrolimus | 8 | 2010 | 350 | 0.300 |
Why?
|
Infant | 17 | 2020 | 13406 | 0.300 |
Why?
|
Caspases | 3 | 2022 | 689 | 0.300 |
Why?
|
DNA | 15 | 2022 | 2741 | 0.290 |
Why?
|
Cloning, Molecular | 6 | 1997 | 1228 | 0.290 |
Why?
|
Granulocyte Colony-Stimulating Factor | 11 | 2009 | 762 | 0.290 |
Why?
|
Protein-Tyrosine Kinases | 8 | 2011 | 1784 | 0.290 |
Why?
|
Multidrug Resistance-Associated Proteins | 2 | 2017 | 86 | 0.280 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2023 | 1619 | 0.280 |
Why?
|
Cytotoxins | 2 | 2020 | 66 | 0.280 |
Why?
|
Pancreatic Neoplasms | 1 | 2024 | 5142 | 0.280 |
Why?
|
Ataxia Telangiectasia Mutated Proteins | 3 | 2015 | 430 | 0.280 |
Why?
|
Ethers, Cyclic | 1 | 2006 | 16 | 0.280 |
Why?
|
Chromosome Aberrations | 12 | 2020 | 1969 | 0.280 |
Why?
|
Philadelphia Chromosome | 4 | 2011 | 801 | 0.280 |
Why?
|
Sweden | 11 | 2016 | 70 | 0.270 |
Why?
|
Poly (ADP-Ribose) Polymerase-1 | 2 | 2022 | 170 | 0.270 |
Why?
|
Bone Marrow Purging | 5 | 2011 | 86 | 0.270 |
Why?
|
Viral Load | 2 | 2018 | 493 | 0.270 |
Why?
|
Incidence | 12 | 2020 | 5773 | 0.270 |
Why?
|
Benzofurans | 1 | 2006 | 39 | 0.270 |
Why?
|
DNA, Complementary | 3 | 1997 | 885 | 0.270 |
Why?
|
Sirolimus | 4 | 2017 | 821 | 0.270 |
Why?
|
Benzoates | 2 | 2024 | 133 | 0.260 |
Why?
|
Time Factors | 27 | 2020 | 13100 | 0.260 |
Why?
|
Fetal Blood | 3 | 2015 | 487 | 0.260 |
Why?
|
Phosphorylation | 4 | 2022 | 4883 | 0.250 |
Why?
|
Cell Cycle Proteins | 2 | 2012 | 2089 | 0.250 |
Why?
|
Chromatin | 2 | 2022 | 957 | 0.250 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2024 | 1513 | 0.250 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2017 | 1052 | 0.250 |
Why?
|
Blood Transfusion | 5 | 2006 | 589 | 0.250 |
Why?
|
Caspase 3 | 2 | 2022 | 482 | 0.250 |
Why?
|
Bone Marrow | 11 | 2020 | 2371 | 0.250 |
Why?
|
Cell Membrane Permeability | 2 | 2016 | 126 | 0.250 |
Why?
|
Piperazines | 5 | 2022 | 2117 | 0.250 |
Why?
|
Potassium | 1 | 2006 | 334 | 0.250 |
Why?
|
Hydrazines | 2 | 2024 | 208 | 0.250 |
Why?
|
Doxorubicin | 10 | 2009 | 3030 | 0.250 |
Why?
|
Animals | 55 | 2021 | 60308 | 0.250 |
Why?
|
Methylprednisolone | 3 | 2009 | 193 | 0.240 |
Why?
|
Neoplasm, Residual | 5 | 2018 | 1691 | 0.240 |
Why?
|
DNA-Binding Proteins | 3 | 2014 | 4870 | 0.240 |
Why?
|
Base Sequence | 16 | 2013 | 4926 | 0.240 |
Why?
|
Antibiotics, Antineoplastic | 5 | 2016 | 728 | 0.240 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2014 | 3592 | 0.240 |
Why?
|
Life Tables | 5 | 2001 | 120 | 0.230 |
Why?
|
Graft Rejection | 4 | 2016 | 839 | 0.230 |
Why?
|
Chromatin Assembly and Disassembly | 2 | 2016 | 291 | 0.230 |
Why?
|
Postoperative Complications | 3 | 2017 | 5624 | 0.230 |
Why?
|
Cell Separation | 7 | 2011 | 617 | 0.230 |
Why?
|
Cyclosporine | 6 | 2016 | 290 | 0.220 |
Why?
|
Administration, Intravenous | 2 | 2023 | 250 | 0.220 |
Why?
|
Blood Platelets | 5 | 2015 | 732 | 0.220 |
Why?
|
Poly ADP Ribosylation | 1 | 2022 | 9 | 0.220 |
Why?
|
Vascular Diseases | 2 | 2016 | 250 | 0.220 |
Why?
|
Polymerase Chain Reaction | 10 | 2017 | 3242 | 0.220 |
Why?
|
Heart Rate | 5 | 1999 | 748 | 0.210 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2022 | 1703 | 0.210 |
Why?
|
Hematopoiesis | 8 | 1998 | 567 | 0.210 |
Why?
|
Tissue Donors | 9 | 2008 | 795 | 0.210 |
Why?
|
Histones | 3 | 2016 | 1472 | 0.210 |
Why?
|
Risk Factors | 22 | 2018 | 17773 | 0.210 |
Why?
|
Anthracenes | 1 | 2022 | 48 | 0.210 |
Why?
|
Heart | 3 | 2003 | 1233 | 0.210 |
Why?
|
Thrombocytopenia | 3 | 2021 | 851 | 0.210 |
Why?
|
Myocardial Ischemia | 2 | 2003 | 442 | 0.210 |
Why?
|
Dental Porcelain | 1 | 2001 | 4 | 0.210 |
Why?
|
Graft vs Host Reaction | 8 | 1998 | 63 | 0.210 |
Why?
|
Dental Implants, Single-Tooth | 1 | 2001 | 2 | 0.210 |
Why?
|
Dental Abutments | 1 | 2001 | 3 | 0.200 |
Why?
|
Methotrexate | 8 | 2010 | 1008 | 0.200 |
Why?
|
Ceramics | 1 | 2001 | 12 | 0.200 |
Why?
|
Combined Modality Therapy | 28 | 2019 | 8939 | 0.200 |
Why?
|
Ventricular Remodeling | 1 | 2003 | 246 | 0.200 |
Why?
|
Chlorambucil | 2 | 2017 | 26 | 0.200 |
Why?
|
Rats | 22 | 1999 | 6177 | 0.200 |
Why?
|
Stroke Volume | 2 | 2003 | 582 | 0.200 |
Why?
|
Real-Time Polymerase Chain Reaction | 2 | 2015 | 1224 | 0.200 |
Why?
|
Rabbits | 7 | 2010 | 973 | 0.200 |
Why?
|
Cytomegalovirus | 3 | 2019 | 480 | 0.200 |
Why?
|
Vascularized Composite Allotransplantation | 1 | 2021 | 29 | 0.190 |
Why?
|
Ifosfamide | 4 | 2009 | 344 | 0.190 |
Why?
|
Genetic Markers | 6 | 2003 | 980 | 0.190 |
Why?
|
Antigens, CD34 | 5 | 2018 | 606 | 0.190 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2016 | 8946 | 0.190 |
Why?
|
Hemorrhagic Disorders | 1 | 2021 | 51 | 0.190 |
Why?
|
STAT5 Transcription Factor | 1 | 2022 | 219 | 0.190 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2020 | 35 | 0.190 |
Why?
|
Carmustine | 5 | 2018 | 215 | 0.190 |
Why?
|
Ethanol | 3 | 1995 | 266 | 0.190 |
Why?
|
Molecular Sequence Data | 18 | 2000 | 6137 | 0.190 |
Why?
|
Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2022 | 284 | 0.180 |
Why?
|
Thrombocythemia, Essential | 1 | 2002 | 163 | 0.180 |
Why?
|
Transplantation Chimera | 7 | 2015 | 168 | 0.180 |
Why?
|
Disease Susceptibility | 2 | 2020 | 542 | 0.180 |
Why?
|
Cosmids | 3 | 1999 | 40 | 0.180 |
Why?
|
Fusion Proteins, bcr-abl | 5 | 2006 | 1110 | 0.180 |
Why?
|
DNA Fragmentation | 1 | 2020 | 201 | 0.170 |
Why?
|
Anthraquinones | 1 | 1999 | 27 | 0.170 |
Why?
|
Bacteriophage M13 | 2 | 1996 | 15 | 0.170 |
Why?
|
Mitochondria, Liver | 4 | 1987 | 52 | 0.170 |
Why?
|
Exercise Test | 2 | 2003 | 301 | 0.170 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 5 | 2013 | 3668 | 0.170 |
Why?
|
Immunologic Memory | 2 | 2023 | 376 | 0.170 |
Why?
|
Blast Crisis | 9 | 2006 | 572 | 0.170 |
Why?
|
Transplant Recipients | 3 | 2020 | 322 | 0.170 |
Why?
|
Cardiac Output, High | 1 | 1999 | 4 | 0.170 |
Why?
|
Intracellular Membranes | 5 | 2016 | 109 | 0.170 |
Why?
|
Antimetabolites, Antineoplastic | 4 | 2014 | 1303 | 0.170 |
Why?
|
DNA Primers | 7 | 2013 | 1423 | 0.170 |
Why?
|
Metabolic Clearance Rate | 2 | 2011 | 236 | 0.170 |
Why?
|
Torque teno virus | 1 | 2018 | 2 | 0.170 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2022 | 406 | 0.170 |
Why?
|
Interferon-gamma | 9 | 2006 | 1167 | 0.170 |
Why?
|
Blood Component Removal | 2 | 2016 | 124 | 0.170 |
Why?
|
Biological Transport | 3 | 2017 | 616 | 0.170 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 1993 | 412 | 0.170 |
Why?
|
Leukocyte Transfusion | 4 | 2012 | 43 | 0.170 |
Why?
|
Critical Care | 2 | 2011 | 793 | 0.170 |
Why?
|
Vagus Nerve | 1 | 1999 | 64 | 0.170 |
Why?
|
DNA Virus Infections | 1 | 2018 | 29 | 0.160 |
Why?
|
Genome, Protozoan | 1 | 1998 | 26 | 0.160 |
Why?
|
Anti-Bacterial Agents | 1 | 2011 | 3022 | 0.160 |
Why?
|
DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2018 | 85 | 0.160 |
Why?
|
Cardiac Output, Low | 1 | 1999 | 82 | 0.160 |
Why?
|
Hematopoietic Stem Cell Mobilization | 3 | 2009 | 273 | 0.160 |
Why?
|
Thymus Neoplasms | 2 | 2023 | 407 | 0.160 |
Why?
|
Radiation Tolerance | 1 | 2002 | 634 | 0.160 |
Why?
|
Pyrazoles | 3 | 2024 | 1488 | 0.160 |
Why?
|
X Chromosome | 3 | 1999 | 345 | 0.160 |
Why?
|
Oxygen Consumption | 6 | 1999 | 399 | 0.160 |
Why?
|
Infant, Newborn | 4 | 2020 | 8299 | 0.160 |
Why?
|
beta Catenin | 1 | 2022 | 696 | 0.150 |
Why?
|
Primary Myelofibrosis | 2 | 2020 | 845 | 0.150 |
Why?
|
Mitochondria | 2 | 2016 | 1297 | 0.150 |
Why?
|
HLA-DRB1 Chains | 1 | 2018 | 87 | 0.150 |
Why?
|
Open Reading Frames | 1 | 1998 | 250 | 0.150 |
Why?
|
Ethacrynic Acid | 1 | 2017 | 9 | 0.150 |
Why?
|
Peroxides | 2 | 1996 | 12 | 0.150 |
Why?
|
fas Receptor | 1 | 1998 | 192 | 0.150 |
Why?
|
Ketoconazole | 1 | 2017 | 34 | 0.150 |
Why?
|
Biological Availability | 3 | 2003 | 231 | 0.150 |
Why?
|
Cell Line | 18 | 2002 | 5135 | 0.150 |
Why?
|
Tandem Repeat Sequences | 2 | 2016 | 201 | 0.150 |
Why?
|
Antigens, CD19 | 1 | 2020 | 581 | 0.150 |
Why?
|
Substance Withdrawal Syndrome | 1 | 1999 | 251 | 0.150 |
Why?
|
Hemodynamics | 4 | 1999 | 952 | 0.150 |
Why?
|
Sorbitol | 2 | 1995 | 29 | 0.150 |
Why?
|
Unrelated Donors | 2 | 2016 | 324 | 0.150 |
Why?
|
In Situ Nick-End Labeling | 2 | 2009 | 464 | 0.150 |
Why?
|
Cell Death | 2 | 2016 | 677 | 0.150 |
Why?
|
Peptidyl-Dipeptidase A | 2 | 1999 | 83 | 0.150 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 1 | 2016 | 12 | 0.150 |
Why?
|
Cytogenetics | 2 | 2014 | 149 | 0.150 |
Why?
|
Age Factors | 10 | 2015 | 5420 | 0.150 |
Why?
|
Adenoviridae Infections | 1 | 2017 | 123 | 0.150 |
Why?
|
Homozygote | 2 | 2016 | 732 | 0.150 |
Why?
|
Coronary Disease | 2 | 1995 | 788 | 0.140 |
Why?
|
Blotting, Western | 2 | 2015 | 3598 | 0.140 |
Why?
|
Templates, Genetic | 1 | 1996 | 87 | 0.140 |
Why?
|
Hypoxia | 4 | 1987 | 454 | 0.140 |
Why?
|
Photosynthetic Reaction Center Complex Proteins | 1 | 1996 | 2 | 0.140 |
Why?
|
Genes, p53 | 2 | 2018 | 1120 | 0.140 |
Why?
|
Hemoglobin E | 1 | 2016 | 1 | 0.140 |
Why?
|
Chloroplasts | 1 | 1996 | 15 | 0.140 |
Why?
|
Urologic Diseases | 1 | 2016 | 77 | 0.140 |
Why?
|
Comorbidity | 2 | 2023 | 2405 | 0.140 |
Why?
|
Gene Duplication | 1 | 2018 | 426 | 0.140 |
Why?
|
Carboprost | 1 | 1995 | 5 | 0.140 |
Why?
|
Receptors, KIR | 1 | 2016 | 62 | 0.140 |
Why?
|
Immunologic Techniques | 1 | 1995 | 43 | 0.140 |
Why?
|
Aflatoxins | 1 | 1995 | 14 | 0.140 |
Why?
|
Blood | 1 | 2016 | 160 | 0.130 |
Why?
|
Red-Cell Aplasia, Pure | 1 | 2016 | 51 | 0.130 |
Why?
|
Mannitol | 1 | 1995 | 54 | 0.130 |
Why?
|
Consensus | 1 | 2020 | 1012 | 0.130 |
Why?
|
Tissue Extracts | 1 | 1995 | 47 | 0.130 |
Why?
|
Aspergillosis | 3 | 2001 | 247 | 0.130 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2021 | 1038 | 0.130 |
Why?
|
Neutrophils | 4 | 2015 | 845 | 0.130 |
Why?
|
Hypoxanthine Phosphoribosyltransferase | 2 | 1992 | 29 | 0.130 |
Why?
|
Liver | 9 | 2005 | 2945 | 0.130 |
Why?
|
Therapeutic Irrigation | 1 | 1995 | 90 | 0.130 |
Why?
|
Severity of Illness Index | 4 | 2016 | 4391 | 0.130 |
Why?
|
Histone Code | 1 | 2016 | 83 | 0.130 |
Why?
|
Antibodies, Monoclonal | 5 | 2009 | 4426 | 0.130 |
Why?
|
Trypanosoma cruzi | 1 | 1998 | 221 | 0.130 |
Why?
|
Consolidation Chemotherapy | 1 | 2016 | 154 | 0.130 |
Why?
|
ABO Blood-Group System | 1 | 2016 | 128 | 0.130 |
Why?
|
Rats, Sprague-Dawley | 5 | 1999 | 2104 | 0.130 |
Why?
|
Pancytopenia | 1 | 2016 | 120 | 0.130 |
Why?
|
CHO Cells | 1 | 1996 | 315 | 0.130 |
Why?
|
N-Glycosyl Hydrolases | 2 | 1996 | 48 | 0.130 |
Why?
|
Power Plants | 1 | 1995 | 4 | 0.130 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 8 | 2004 | 2402 | 0.130 |
Why?
|
Leukemia, Radiation-Induced | 1 | 1995 | 24 | 0.130 |
Why?
|
Chromosome Mapping | 4 | 2003 | 1496 | 0.130 |
Why?
|
Fucose | 1 | 2015 | 51 | 0.130 |
Why?
|
Minisatellite Repeats | 1 | 1995 | 52 | 0.130 |
Why?
|
Neonatal Screening | 1 | 2016 | 170 | 0.130 |
Why?
|
Renin-Angiotensin System | 1 | 1995 | 106 | 0.130 |
Why?
|
Acetamides | 3 | 2023 | 114 | 0.130 |
Why?
|
Adenosine | 2 | 2001 | 292 | 0.130 |
Why?
|
Oncogene Proteins | 2 | 1999 | 362 | 0.120 |
Why?
|
Genes | 1 | 1996 | 480 | 0.120 |
Why?
|
Maintenance Chemotherapy | 1 | 2015 | 208 | 0.120 |
Why?
|
Alleles | 5 | 2016 | 2462 | 0.120 |
Why?
|
Protein Kinase Inhibitors | 5 | 2011 | 4803 | 0.120 |
Why?
|
Angiotensin II | 1 | 1995 | 198 | 0.120 |
Why?
|
Cardiotonic Agents | 1 | 1995 | 156 | 0.120 |
Why?
|
Salmon | 1 | 2014 | 7 | 0.120 |
Why?
|
Carcinogens | 1 | 1995 | 387 | 0.120 |
Why?
|
Kidney Transplantation | 1 | 2020 | 765 | 0.120 |
Why?
|
Food Contamination | 1 | 2014 | 25 | 0.120 |
Why?
|
Metabolic Networks and Pathways | 1 | 2016 | 337 | 0.120 |
Why?
|
Tumor Protein p73 | 1 | 2014 | 111 | 0.120 |
Why?
|
Drug Resistance, Multiple | 1 | 1995 | 210 | 0.120 |
Why?
|
Drug Resistance | 11 | 2005 | 597 | 0.120 |
Why?
|
Listeriosis | 1 | 2014 | 36 | 0.120 |
Why?
|
Granulocyte Precursor Cells | 1 | 2013 | 37 | 0.120 |
Why?
|
DNA Glycosylases | 1 | 1994 | 92 | 0.120 |
Why?
|
Listeria monocytogenes | 1 | 2014 | 53 | 0.120 |
Why?
|
Hypertension, Pulmonary | 1 | 1999 | 449 | 0.120 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 1995 | 363 | 0.120 |
Why?
|
Reproducibility of Results | 3 | 2017 | 6072 | 0.120 |
Why?
|
Glycine | 1 | 1995 | 293 | 0.110 |
Why?
|
Receptors, Adrenergic, beta | 1 | 1993 | 98 | 0.110 |
Why?
|
Heart Diseases | 3 | 2016 | 736 | 0.110 |
Why?
|
Neutropenia | 6 | 2015 | 967 | 0.110 |
Why?
|
Diastole | 1 | 1993 | 187 | 0.110 |
Why?
|
Statistics, Nonparametric | 4 | 2012 | 993 | 0.110 |
Why?
|
Recombinant Proteins | 15 | 2009 | 2945 | 0.110 |
Why?
|
Kinetics | 13 | 2002 | 2091 | 0.110 |
Why?
|
Proto-Oncogene Proteins | 3 | 1999 | 2533 | 0.110 |
Why?
|
Karyotyping | 9 | 1995 | 1020 | 0.110 |
Why?
|
Biotransformation | 6 | 2002 | 93 | 0.110 |
Why?
|
RNA, Messenger | 6 | 2016 | 6222 | 0.110 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 3 | 1985 | 224 | 0.110 |
Why?
|
Cluster Analysis | 1 | 1995 | 1062 | 0.100 |
Why?
|
Checkpoint Kinase 2 | 1 | 2012 | 127 | 0.100 |
Why?
|
Gingival Hemorrhage | 2 | 2001 | 3 | 0.100 |
Why?
|
Adenoviridae | 1 | 2017 | 1472 | 0.100 |
Why?
|
Dental Restoration Failure | 2 | 2001 | 5 | 0.100 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2016 | 1552 | 0.100 |
Why?
|
Oxidative Stress | 1 | 2018 | 1147 | 0.100 |
Why?
|
Guillain-Barre Syndrome | 1 | 2012 | 36 | 0.100 |
Why?
|
Leukemia, Myelomonocytic, Acute | 1 | 1992 | 72 | 0.100 |
Why?
|
Blood Transfusion, Autologous | 3 | 1997 | 69 | 0.100 |
Why?
|
Esthetics, Dental | 2 | 2001 | 18 | 0.100 |
Why?
|
Dental Prosthesis Design | 2 | 2001 | 17 | 0.100 |
Why?
|
Lymphocytes | 7 | 1992 | 1239 | 0.100 |
Why?
|
Half-Life | 2 | 2011 | 265 | 0.100 |
Why?
|
Histocompatibility | 4 | 2011 | 184 | 0.100 |
Why?
|
In Vitro Techniques | 10 | 1992 | 1635 | 0.100 |
Why?
|
Heart Valve Prosthesis | 1 | 1995 | 390 | 0.100 |
Why?
|
Cytogenetic Analysis | 3 | 2020 | 570 | 0.100 |
Why?
|
Kidney Diseases | 2 | 2016 | 699 | 0.100 |
Why?
|
Adenosine Deaminase Inhibitors | 1 | 2010 | 24 | 0.100 |
Why?
|
Agranulocytosis | 1 | 1990 | 78 | 0.100 |
Why?
|
Mesenchymal Stem Cell Transplantation | 1 | 2012 | 205 | 0.100 |
Why?
|
Imines | 1 | 1990 | 14 | 0.090 |
Why?
|
Quinones | 1 | 1990 | 23 | 0.090 |
Why?
|
Drugs, Generic | 1 | 2010 | 35 | 0.090 |
Why?
|
Endotoxins | 3 | 2002 | 98 | 0.090 |
Why?
|
Precision Medicine | 1 | 2018 | 1167 | 0.090 |
Why?
|
Pentostatin | 1 | 2010 | 120 | 0.090 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2011 | 869 | 0.090 |
Why?
|
Tumor Microenvironment | 1 | 2021 | 2887 | 0.090 |
Why?
|
Enterocolitis, Pseudomembranous | 1 | 2011 | 111 | 0.090 |
Why?
|
Coronary Artery Bypass | 1 | 1995 | 716 | 0.090 |
Why?
|
Polyethylene Glycols | 4 | 2000 | 625 | 0.090 |
Why?
|
Intercalating Agents | 2 | 1987 | 30 | 0.090 |
Why?
|
Acetylation | 1 | 2011 | 515 | 0.090 |
Why?
|
Secondary Prevention | 1 | 2012 | 332 | 0.090 |
Why?
|
Thalidomide | 2 | 2015 | 575 | 0.090 |
Why?
|
Antiviral Agents | 1 | 2017 | 1247 | 0.090 |
Why?
|
Hospitalization | 2 | 2004 | 2117 | 0.090 |
Why?
|
Cell Cycle Checkpoints | 1 | 2011 | 277 | 0.090 |
Why?
|
Ganciclovir | 3 | 1997 | 177 | 0.090 |
Why?
|
Prostate | 1 | 1995 | 1099 | 0.090 |
Why?
|
Up-Regulation | 1 | 2016 | 2477 | 0.090 |
Why?
|
Benzoquinones | 1 | 1990 | 111 | 0.090 |
Why?
|
Acetaminophen | 2 | 1982 | 118 | 0.090 |
Why?
|
Genetic Variation | 1 | 2018 | 2102 | 0.090 |
Why?
|
Living Donors | 1 | 2010 | 178 | 0.090 |
Why?
|
Cytosol | 4 | 1996 | 238 | 0.090 |
Why?
|
Nutrition Disorders | 1 | 1990 | 58 | 0.090 |
Why?
|
Gated Blood-Pool Imaging | 2 | 2003 | 17 | 0.090 |
Why?
|
Cohort Studies | 7 | 2015 | 9315 | 0.090 |
Why?
|
RNA Splicing | 1 | 1992 | 372 | 0.090 |
Why?
|
DNA (Cytosine-5-)-Methyltransferases | 1 | 2012 | 306 | 0.090 |
Why?
|
Leukocytes, Mononuclear | 2 | 2006 | 713 | 0.090 |
Why?
|
Feasibility Studies | 7 | 2023 | 2324 | 0.090 |
Why?
|
Gene Expression Profiling | 3 | 2008 | 5194 | 0.090 |
Why?
|
Blood Group Antigens | 1 | 1990 | 91 | 0.090 |
Why?
|
Glutamine | 1 | 2011 | 300 | 0.090 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2018 | 2289 | 0.090 |
Why?
|
Cell Culture Techniques | 2 | 2012 | 608 | 0.090 |
Why?
|
Boronic Acids | 1 | 2011 | 364 | 0.080 |
Why?
|
Contraindications | 2 | 2002 | 152 | 0.080 |
Why?
|
Influenza, Human | 1 | 2016 | 934 | 0.080 |
Why?
|
Genotype | 2 | 2016 | 4158 | 0.080 |
Why?
|
Respiratory Insufficiency | 2 | 1990 | 337 | 0.080 |
Why?
|
Lung Diseases | 3 | 2001 | 725 | 0.080 |
Why?
|
Drug Stability | 3 | 1997 | 109 | 0.080 |
Why?
|
HLA-DQ Antigens | 2 | 2000 | 60 | 0.080 |
Why?
|
Measles virus | 2 | 1999 | 14 | 0.080 |
Why?
|
Solvents | 3 | 2000 | 66 | 0.080 |
Why?
|
HLA-DR Antigens | 2 | 2000 | 181 | 0.080 |
Why?
|
Practice Patterns, Physicians' | 1 | 2017 | 1319 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2016 | 2082 | 0.080 |
Why?
|
Cells, Cultured | 9 | 2008 | 5665 | 0.080 |
Why?
|
Ethylenediamines | 1 | 2008 | 21 | 0.080 |
Why?
|
Pyrimidines | 4 | 2009 | 3565 | 0.080 |
Why?
|
Pyrazines | 1 | 2011 | 497 | 0.080 |
Why?
|
Pneumonia, Bacterial | 1 | 2009 | 130 | 0.080 |
Why?
|
Receptors, Interleukin-2 | 3 | 2000 | 186 | 0.080 |
Why?
|
HIV-1 | 1 | 1993 | 671 | 0.080 |
Why?
|
Solubility | 3 | 1997 | 248 | 0.080 |
Why?
|
Receptors, Angiotensin | 2 | 1999 | 45 | 0.080 |
Why?
|
Glutathione | 4 | 2002 | 368 | 0.080 |
Why?
|
Delayed Diagnosis | 1 | 2009 | 147 | 0.080 |
Why?
|
Glomerular Filtration Rate | 3 | 2016 | 607 | 0.080 |
Why?
|
Amphotericin B | 4 | 2001 | 291 | 0.080 |
Why?
|
Nutritional Status | 1 | 1990 | 338 | 0.080 |
Why?
|
G2 Phase | 1 | 2008 | 212 | 0.080 |
Why?
|
Cytokines | 6 | 2005 | 2851 | 0.080 |
Why?
|
Imides | 1 | 1987 | 10 | 0.070 |
Why?
|
Chi-Square Distribution | 3 | 2003 | 1339 | 0.070 |
Why?
|
Chelating Agents | 1 | 2008 | 132 | 0.070 |
Why?
|
Phenetidine | 2 | 1985 | 2 | 0.070 |
Why?
|
Bone Marrow Cells | 11 | 1999 | 948 | 0.070 |
Why?
|
Verapamil | 1 | 1987 | 79 | 0.070 |
Why?
|
Lymphocyte Transfusion | 3 | 2004 | 180 | 0.070 |
Why?
|
Aminophenols | 2 | 1985 | 12 | 0.070 |
Why?
|
Energy Metabolism | 2 | 1990 | 1002 | 0.070 |
Why?
|
Graft vs Tumor Effect | 2 | 2004 | 140 | 0.070 |
Why?
|
Neoplastic Stem Cells | 4 | 1995 | 1451 | 0.070 |
Why?
|
Copper | 1 | 2008 | 168 | 0.070 |
Why?
|
Aminoglycosides | 1 | 2007 | 223 | 0.070 |
Why?
|
Gene Library | 3 | 1997 | 295 | 0.070 |
Why?
|
Tumor Necrosis Factor-alpha | 6 | 2004 | 1583 | 0.070 |
Why?
|
Hydrogen-Ion Concentration | 4 | 1997 | 607 | 0.070 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2008 | 197 | 0.070 |
Why?
|
Isoquinolines | 1 | 1987 | 119 | 0.070 |
Why?
|
Immune Tolerance | 2 | 2006 | 407 | 0.070 |
Why?
|
Interleukin-6 | 5 | 1995 | 1048 | 0.070 |
Why?
|
Radioimmunotherapy | 2 | 1997 | 121 | 0.070 |
Why?
|
Hepatectomy | 1 | 2013 | 1015 | 0.070 |
Why?
|
Ions | 2 | 1987 | 55 | 0.070 |
Why?
|
Social Security | 1 | 2006 | 3 | 0.070 |
Why?
|
Rehabilitation, Vocational | 1 | 2006 | 7 | 0.070 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2008 | 324 | 0.070 |
Why?
|
Graft Enhancement, Immunologic | 2 | 2012 | 37 | 0.070 |
Why?
|
Retroviridae | 4 | 1993 | 327 | 0.070 |
Why?
|
Idarubicin | 4 | 2000 | 447 | 0.070 |
Why?
|
Water | 3 | 1997 | 371 | 0.070 |
Why?
|
Mitoxantrone | 4 | 1999 | 219 | 0.070 |
Why?
|
Gene Expression | 2 | 2009 | 3600 | 0.070 |
Why?
|
Bronchoscopy | 1 | 2009 | 475 | 0.070 |
Why?
|
Blood Cell Count | 5 | 2012 | 226 | 0.070 |
Why?
|
Risk Assessment | 5 | 2020 | 6936 | 0.070 |
Why?
|
Leukapheresis | 3 | 2009 | 162 | 0.070 |
Why?
|
Encephalitis, Herpes Simplex | 1 | 2005 | 9 | 0.070 |
Why?
|
Lorazepam | 1 | 1986 | 41 | 0.070 |
Why?
|
Age Distribution | 3 | 2014 | 703 | 0.070 |
Why?
|
Granulocytes | 7 | 1997 | 226 | 0.070 |
Why?
|
Immunophenotyping | 6 | 2016 | 1696 | 0.070 |
Why?
|
Peroxidases | 2 | 1983 | 29 | 0.070 |
Why?
|
Rituximab | 3 | 2023 | 1534 | 0.070 |
Why?
|
Filgrastim | 6 | 2009 | 192 | 0.070 |
Why?
|
Ferritins | 2 | 2014 | 152 | 0.070 |
Why?
|
Proportional Hazards Models | 5 | 2016 | 5036 | 0.070 |
Why?
|
Th1 Cells | 2 | 2016 | 257 | 0.070 |
Why?
|
Digitonin | 1 | 1985 | 4 | 0.070 |
Why?
|
Adenosine Triphosphate | 3 | 1996 | 582 | 0.070 |
Why?
|
Kidney Function Tests | 2 | 2016 | 192 | 0.070 |
Why?
|
Haloperidol | 1 | 1986 | 66 | 0.070 |
Why?
|
Antigens, CD | 5 | 2007 | 1407 | 0.070 |
Why?
|
Neurocognitive Disorders | 1 | 1986 | 69 | 0.060 |
Why?
|
Photopheresis | 1 | 2005 | 81 | 0.060 |
Why?
|
Lipid Peroxidation | 2 | 1996 | 157 | 0.060 |
Why?
|
Membrane Proteins | 1 | 1996 | 2871 | 0.060 |
Why?
|
Employment | 1 | 2006 | 117 | 0.060 |
Why?
|
Mycoses | 3 | 2004 | 386 | 0.060 |
Why?
|
Genetic Vectors | 3 | 1996 | 1727 | 0.060 |
Why?
|
CD8 Antigens | 4 | 1992 | 173 | 0.060 |
Why?
|
Antifungal Agents | 4 | 2001 | 848 | 0.060 |
Why?
|
Herpes Simplex | 1 | 2005 | 95 | 0.060 |
Why?
|
Leukemia, Lymphoid | 2 | 1985 | 280 | 0.060 |
Why?
|
Point Mutation | 2 | 2006 | 775 | 0.060 |
Why?
|
Double-Blind Method | 3 | 2011 | 2632 | 0.060 |
Why?
|
Cell Division | 8 | 1995 | 2557 | 0.060 |
Why?
|
Mutation | 6 | 2017 | 15373 | 0.060 |
Why?
|
Interleukin-1 | 4 | 1996 | 477 | 0.060 |
Why?
|
Enzyme Activation | 1 | 2008 | 1795 | 0.060 |
Why?
|
Texas | 2 | 2012 | 6357 | 0.060 |
Why?
|
Emergencies | 1 | 1986 | 206 | 0.060 |
Why?
|
CD4 Antigens | 2 | 2016 | 174 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 4 | 2019 | 6229 | 0.060 |
Why?
|
Preoperative Care | 1 | 2010 | 1536 | 0.060 |
Why?
|
DNA Topoisomerases, Type II | 4 | 1990 | 118 | 0.060 |
Why?
|
Histocompatibility Antigens | 2 | 1974 | 74 | 0.060 |
Why?
|
Patient Selection | 4 | 2006 | 2072 | 0.060 |
Why?
|
NADP | 2 | 1996 | 96 | 0.060 |
Why?
|
Microscopy, Electron | 5 | 1996 | 613 | 0.060 |
Why?
|
Harmine | 2 | 1980 | 3 | 0.060 |
Why?
|
Leukocyte Count | 5 | 2002 | 701 | 0.060 |
Why?
|
Pinus sylvestris | 1 | 2003 | 1 | 0.060 |
Why?
|
Risk | 3 | 2017 | 1991 | 0.060 |
Why?
|
Chronic Disease | 7 | 2005 | 1865 | 0.060 |
Why?
|
Postmortem Changes | 1 | 1983 | 15 | 0.060 |
Why?
|
Blood Donors | 3 | 2012 | 166 | 0.060 |
Why?
|
Electrophoresis | 2 | 1993 | 60 | 0.060 |
Why?
|
Delirium | 1 | 1986 | 205 | 0.060 |
Why?
|
Translocation, Genetic | 3 | 2000 | 1254 | 0.060 |
Why?
|
Cardiomyopathies | 2 | 1993 | 603 | 0.060 |
Why?
|
Thiazoles | 1 | 2007 | 729 | 0.050 |
Why?
|
Hydrogen Peroxide | 2 | 1983 | 220 | 0.050 |
Why?
|
Rhodamines | 2 | 2016 | 49 | 0.050 |
Why?
|
Cisplatin | 5 | 1999 | 2444 | 0.050 |
Why?
|
Social Support | 1 | 2006 | 564 | 0.050 |
Why?
|
Leukemia, Experimental | 2 | 1981 | 78 | 0.050 |
Why?
|
Vincristine | 2 | 2009 | 1518 | 0.050 |
Why?
|
Carcinoma, Transitional Cell | 1 | 1990 | 980 | 0.050 |
Why?
|
Erythropoiesis | 2 | 1973 | 74 | 0.050 |
Why?
|
Nuclear Proteins | 1 | 2014 | 3359 | 0.050 |
Why?
|
Polymorphism, Genetic | 2 | 1999 | 1475 | 0.050 |
Why?
|
T-Lymphocyte Subsets | 2 | 1999 | 596 | 0.050 |
Why?
|
Prednimustine | 1 | 1982 | 1 | 0.050 |
Why?
|
Ventricular Function, Left | 3 | 2014 | 608 | 0.050 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 2 | 2010 | 600 | 0.050 |
Why?
|
Chemistry | 3 | 1991 | 99 | 0.050 |
Why?
|
Metal Ceramic Alloys | 1 | 2001 | 1 | 0.050 |
Why?
|
Root Canal Therapy | 1 | 2001 | 2 | 0.050 |
Why?
|
Bicuspid | 1 | 2001 | 3 | 0.050 |
Why?
|
Cuspid | 1 | 2001 | 3 | 0.050 |
Why?
|
Chemical Phenomena | 3 | 1991 | 137 | 0.050 |
Why?
|
Incisor | 1 | 2001 | 11 | 0.050 |
Why?
|
Multivariate Analysis | 5 | 2007 | 4350 | 0.050 |
Why?
|
Brain | 1 | 1995 | 4139 | 0.050 |
Why?
|
Thioguanine | 1 | 1982 | 69 | 0.050 |
Why?
|
Molar | 1 | 2001 | 14 | 0.050 |
Why?
|
Tooth Preparation, Prosthodontic | 1 | 2001 | 1 | 0.050 |
Why?
|
Pilot Projects | 8 | 2008 | 2818 | 0.050 |
Why?
|
Mycophenolic Acid | 2 | 2014 | 150 | 0.050 |
Why?
|
Alveolar Bone Loss | 1 | 2001 | 8 | 0.050 |
Why?
|
Xeroderma Pigmentosum | 1 | 2002 | 70 | 0.050 |
Why?
|
Dental Plaque | 1 | 2001 | 10 | 0.050 |
Why?
|
Treatment Failure | 3 | 2017 | 1430 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-bcr | 3 | 1999 | 66 | 0.050 |
Why?
|
Pancreatitis | 1 | 2004 | 276 | 0.050 |
Why?
|
Spleen | 7 | 1975 | 687 | 0.050 |
Why?
|
Dental Prosthesis, Implant-Supported | 1 | 2001 | 17 | 0.050 |
Why?
|
Clinical Trials as Topic | 4 | 2019 | 3793 | 0.050 |
Why?
|
Thrombopoietin | 1 | 2002 | 84 | 0.050 |
Why?
|
Sarcoma, Experimental | 2 | 1992 | 68 | 0.050 |
Why?
|
Immunoglobulins | 3 | 1996 | 269 | 0.050 |
Why?
|
Titanium | 1 | 2001 | 64 | 0.050 |
Why?
|
Surface Properties | 1 | 2001 | 183 | 0.050 |
Why?
|
Glucocorticoids | 1 | 2005 | 640 | 0.050 |
Why?
|
Neoplasm Staging | 2 | 2016 | 13766 | 0.050 |
Why?
|
STAT3 Transcription Factor | 1 | 2008 | 1128 | 0.050 |
Why?
|
Probability | 2 | 2004 | 883 | 0.050 |
Why?
|
Mitral Valve Insufficiency | 1 | 2003 | 184 | 0.050 |
Why?
|
Rats, Inbred Strains | 3 | 1990 | 408 | 0.050 |
Why?
|
Aged, 80 and over | 12 | 2014 | 30222 | 0.050 |
Why?
|
Sequence Homology, Nucleic Acid | 2 | 1998 | 356 | 0.050 |
Why?
|
Antigens, Viral | 3 | 1999 | 478 | 0.050 |
Why?
|
Indium Radioisotopes | 2 | 1997 | 65 | 0.050 |
Why?
|
Cell Hypoxia | 1 | 2002 | 334 | 0.050 |
Why?
|
Ischemic Attack, Transient | 1 | 1981 | 57 | 0.050 |
Why?
|
Gamma Rays | 1 | 2002 | 242 | 0.050 |
Why?
|
Arthritis, Rheumatoid | 1 | 2006 | 491 | 0.050 |
Why?
|
Stress, Mechanical | 1 | 2001 | 317 | 0.050 |
Why?
|
Mitochondria, Heart | 2 | 1996 | 76 | 0.050 |
Why?
|
Foscarnet | 2 | 1997 | 17 | 0.050 |
Why?
|
Glutathione Transferase | 1 | 2002 | 364 | 0.050 |
Why?
|
Cell- and Tissue-Based Therapy | 1 | 2023 | 410 | 0.050 |
Why?
|
Leukocytes | 1 | 2002 | 422 | 0.050 |
Why?
|
Liver Neoplasms | 2 | 2013 | 4617 | 0.050 |
Why?
|
Aspergillus fumigatus | 1 | 2001 | 139 | 0.050 |
Why?
|
Germinal Center | 1 | 2021 | 166 | 0.050 |
Why?
|
Oncogenes | 3 | 1989 | 674 | 0.050 |
Why?
|
Antipsychotic Agents | 1 | 1984 | 423 | 0.040 |
Why?
|
Sulfhydryl Compounds | 2 | 1996 | 72 | 0.040 |
Why?
|
Statistics as Topic | 1 | 2001 | 453 | 0.040 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2007 | 2522 | 0.040 |
Why?
|
Cerebrovascular Disorders | 1 | 1981 | 150 | 0.040 |
Why?
|
Cause of Death | 2 | 2012 | 768 | 0.040 |
Why?
|
Carubicin | 1 | 1999 | 2 | 0.040 |
Why?
|
H-2 Antigens | 1 | 1979 | 39 | 0.040 |
Why?
|
Exons | 3 | 1993 | 1356 | 0.040 |
Why?
|
Alkaloids | 1 | 1979 | 80 | 0.040 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 2000 | 172 | 0.040 |
Why?
|
Echocardiography | 2 | 1996 | 1196 | 0.040 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2001 | 187 | 0.040 |
Why?
|
Yttrium Radioisotopes | 2 | 1997 | 179 | 0.040 |
Why?
|
Biomarkers, Tumor | 4 | 2020 | 10430 | 0.040 |
Why?
|
Cell Differentiation | 8 | 2023 | 4106 | 0.040 |
Why?
|
Perfusion | 2 | 1996 | 295 | 0.040 |
Why?
|
NAD | 2 | 1996 | 90 | 0.040 |
Why?
|
Butyrophenones | 1 | 2019 | 12 | 0.040 |
Why?
|
Restriction Mapping | 2 | 1997 | 266 | 0.040 |
Why?
|
Tumor Burden | 1 | 2005 | 2010 | 0.040 |
Why?
|
Ascites | 1 | 2020 | 199 | 0.040 |
Why?
|
Epirubicin | 1 | 1999 | 157 | 0.040 |
Why?
|
Substance-Related Disorders | 1 | 1984 | 543 | 0.040 |
Why?
|
Neoplasms, Experimental | 2 | 1980 | 743 | 0.040 |
Why?
|
DNA, Neoplasm | 4 | 1992 | 1929 | 0.040 |
Why?
|
Cell Size | 1 | 1999 | 146 | 0.040 |
Why?
|
Intestinal Absorption | 1 | 2000 | 221 | 0.040 |
Why?
|
Electrocardiography, Ambulatory | 1 | 1999 | 68 | 0.040 |
Why?
|
Bacterial Infections | 2 | 2004 | 486 | 0.040 |
Why?
|
Lymphocyte Subsets | 2 | 1996 | 139 | 0.040 |
Why?
|
Herpesvirus 3, Human | 1 | 1999 | 45 | 0.040 |
Why?
|
Calcium | 3 | 1987 | 1581 | 0.040 |
Why?
|
ATP Synthetase Complexes | 1 | 1998 | 5 | 0.040 |
Why?
|
Inhibitory Concentration 50 | 1 | 1999 | 292 | 0.040 |
Why?
|
Phosphotransferases (Phosphate Group Acceptor) | 1 | 1998 | 9 | 0.040 |
Why?
|
Ribonucleoprotein, U2 Small Nuclear | 1 | 1998 | 24 | 0.040 |
Why?
|
Vascular Access Devices | 1 | 2019 | 50 | 0.040 |
Why?
|
Glucose-6-Phosphate Isomerase | 1 | 1998 | 25 | 0.040 |
Why?
|
DNA, Protozoan | 1 | 1998 | 35 | 0.040 |
Why?
|
Ventricular Fibrillation | 1 | 1999 | 63 | 0.040 |
Why?
|
Interleukin-10 | 2 | 1999 | 490 | 0.040 |
Why?
|
Radiography, Thoracic | 2 | 1992 | 461 | 0.040 |
Why?
|
Sex Distribution | 2 | 2014 | 495 | 0.040 |
Why?
|
Fever | 3 | 1997 | 500 | 0.040 |
Why?
|
DNA Topoisomerases, Type I | 2 | 1990 | 57 | 0.040 |
Why?
|
HL-60 Cells | 2 | 1996 | 306 | 0.040 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2002 | 457 | 0.040 |
Why?
|
Protein Biosynthesis | 1 | 2002 | 909 | 0.040 |
Why?
|
Imatinib Mesylate | 3 | 2009 | 1685 | 0.040 |
Why?
|
Mice | 17 | 1995 | 34862 | 0.040 |
Why?
|
Ribosomal Proteins | 1 | 1999 | 119 | 0.040 |
Why?
|
Radiographic Image Enhancement | 2 | 1992 | 405 | 0.040 |
Why?
|
CD5 Antigens | 1 | 1999 | 116 | 0.040 |
Why?
|
Drug Carriers | 1 | 2000 | 329 | 0.040 |
Why?
|
Fanconi Anemia | 1 | 1999 | 89 | 0.040 |
Why?
|
Pseudogenes | 1 | 1998 | 84 | 0.040 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2000 | 404 | 0.040 |
Why?
|
Sulfurtransferases | 1 | 1977 | 2 | 0.040 |
Why?
|
Thiosulfate Sulfurtransferase | 1 | 1977 | 4 | 0.040 |
Why?
|
Enzymes, Immobilized | 1 | 1977 | 10 | 0.040 |
Why?
|
Lyases | 1 | 1977 | 12 | 0.040 |
Why?
|
Vascular Resistance | 1 | 1999 | 200 | 0.040 |
Why?
|
Aminoacridines | 3 | 1986 | 23 | 0.040 |
Why?
|
Membrane Potentials | 4 | 1987 | 433 | 0.040 |
Why?
|
Colony-Forming Units Assay | 5 | 1995 | 253 | 0.040 |
Why?
|
Odds Ratio | 2 | 2013 | 2333 | 0.040 |
Why?
|
Safety | 1 | 2000 | 472 | 0.040 |
Why?
|
Solutions | 1 | 1997 | 106 | 0.040 |
Why?
|
Indicators and Reagents | 1 | 1997 | 132 | 0.040 |
Why?
|
Platelet Transfusion | 2 | 2015 | 156 | 0.040 |
Why?
|
Beijing | 1 | 2017 | 13 | 0.040 |
Why?
|
Measles Vaccine | 1 | 1997 | 11 | 0.040 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 1998 | 220 | 0.040 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 1998 | 188 | 0.040 |
Why?
|
Alanine Transaminase | 1 | 1998 | 228 | 0.040 |
Why?
|
Databases, Factual | 3 | 2014 | 2246 | 0.040 |
Why?
|
Plants | 1 | 1977 | 59 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2013 | 3627 | 0.040 |
Why?
|
Protozoan Proteins | 1 | 1998 | 121 | 0.040 |
Why?
|
Oxygen | 1 | 2002 | 765 | 0.040 |
Why?
|
Alcoholism | 1 | 1980 | 307 | 0.040 |
Why?
|
Cell Membrane | 2 | 1994 | 866 | 0.040 |
Why?
|
Bilirubin | 1 | 1998 | 222 | 0.040 |
Why?
|
Multienzyme Complexes | 1 | 1998 | 223 | 0.040 |
Why?
|
B-Lymphocytes | 4 | 1992 | 1316 | 0.040 |
Why?
|
Quinazolines | 1 | 2002 | 929 | 0.040 |
Why?
|
Benzamides | 3 | 2009 | 1867 | 0.040 |
Why?
|
Cysteine Endopeptidases | 1 | 1998 | 256 | 0.040 |
Why?
|
Cell Transformation, Neoplastic | 3 | 2010 | 2383 | 0.040 |
Why?
|
Asia | 1 | 2017 | 144 | 0.040 |
Why?
|
Myocardial Infarction | 1 | 1986 | 1426 | 0.040 |
Why?
|
Urinary Bladder Neoplasms | 1 | 1990 | 2383 | 0.040 |
Why?
|
Patient Admission | 1 | 1998 | 221 | 0.040 |
Why?
|
Intensive Care Units | 2 | 2011 | 730 | 0.040 |
Why?
|
Clone Cells | 4 | 1988 | 551 | 0.040 |
Why?
|
Neoplasm Transplantation | 3 | 1995 | 1533 | 0.040 |
Why?
|
Erythema Infectiosum | 1 | 2016 | 11 | 0.040 |
Why?
|
Radioimmunodetection | 1 | 1996 | 16 | 0.040 |
Why?
|
Sepsis | 1 | 2002 | 668 | 0.040 |
Why?
|
Contig Mapping | 1 | 2016 | 61 | 0.040 |
Why?
|
Infliximab | 2 | 2009 | 138 | 0.040 |
Why?
|
Immunoglobulin G | 2 | 2000 | 1044 | 0.040 |
Why?
|
Parvovirus B19, Human | 1 | 2016 | 40 | 0.040 |
Why?
|
Orthomyxoviridae | 1 | 2016 | 95 | 0.040 |
Why?
|
Adenosine Diphosphate | 1 | 1996 | 115 | 0.040 |
Why?
|
Spectrophotometry, Atomic | 1 | 1996 | 14 | 0.040 |
Why?
|
Photosystem II Protein Complex | 1 | 1996 | 3 | 0.040 |
Why?
|
Cytochromes | 1 | 1996 | 10 | 0.040 |
Why?
|
Spinacia oleracea | 1 | 1996 | 10 | 0.030 |
Why?
|
Pigments, Biological | 1 | 1996 | 12 | 0.030 |
Why?
|
Microsatellite Repeats | 1 | 1998 | 595 | 0.030 |
Why?
|
Sampling Studies | 1 | 2016 | 171 | 0.030 |
Why?
|
Endogenous Retroviruses | 1 | 2016 | 42 | 0.030 |
Why?
|
Chromatography | 1 | 1996 | 50 | 0.030 |
Why?
|
Prevalence | 2 | 2014 | 3295 | 0.030 |
Why?
|
Mice, Nude | 2 | 1995 | 4340 | 0.030 |
Why?
|
Endotoxemia | 1 | 1997 | 65 | 0.030 |
Why?
|
tert-Butylhydroperoxide | 1 | 1996 | 7 | 0.030 |
Why?
|
Chaperonin 60 | 1 | 1996 | 46 | 0.030 |
Why?
|
Aflatoxin M1 | 1 | 1995 | 2 | 0.030 |
Why?
|
Th2 Cells | 1 | 1997 | 261 | 0.030 |
Why?
|
Aflatoxin B1 | 1 | 1995 | 9 | 0.030 |
Why?
|
Oxidation-Reduction | 6 | 1996 | 723 | 0.030 |
Why?
|
Myoglobin | 1 | 1996 | 116 | 0.030 |
Why?
|
Respiration | 1 | 1998 | 447 | 0.030 |
Why?
|
Hematology | 1 | 2017 | 102 | 0.030 |
Why?
|
Chemistry, Pharmaceutical | 1 | 1996 | 86 | 0.030 |
Why?
|
Dogs | 1 | 1997 | 1174 | 0.030 |
Why?
|
Preoperative Period | 1 | 2017 | 344 | 0.030 |
Why?
|
Blood Specimen Collection | 1 | 2016 | 94 | 0.030 |
Why?
|
Case-Control Studies | 3 | 2005 | 6153 | 0.030 |
Why?
|
Genotyping Techniques | 1 | 2016 | 166 | 0.030 |
Why?
|
Herpesvirus 6, Human | 1 | 2016 | 79 | 0.030 |
Why?
|
Interferon Type I | 2 | 1995 | 252 | 0.030 |
Why?
|
Osmolar Concentration | 1 | 1996 | 205 | 0.030 |
Why?
|
Cell Cycle | 1 | 2002 | 2115 | 0.030 |
Why?
|
Recombination, Genetic | 1 | 1998 | 625 | 0.030 |
Why?
|
Bacteriophages | 1 | 2016 | 72 | 0.030 |
Why?
|
Exercise | 1 | 2003 | 1194 | 0.030 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 1998 | 343 | 0.030 |
Why?
|
China | 1 | 2017 | 618 | 0.030 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 1996 | 115 | 0.030 |
Why?
|
Lung | 2 | 2001 | 3196 | 0.030 |
Why?
|
Hemolysis | 1 | 1996 | 128 | 0.030 |
Why?
|
Sinusitis | 1 | 1997 | 134 | 0.030 |
Why?
|
Lipoproteins, LDL | 1 | 1996 | 164 | 0.030 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 1996 | 573 | 0.030 |
Why?
|
Water-Electrolyte Balance | 1 | 1995 | 105 | 0.030 |
Why?
|
Interferon-alpha | 2 | 1995 | 908 | 0.030 |
Why?
|
Administration, Intravesical | 1 | 1995 | 167 | 0.030 |
Why?
|
Space-Time Clustering | 1 | 1995 | 2 | 0.030 |
Why?
|
Erythrocytes | 2 | 1973 | 342 | 0.030 |
Why?
|
Protein C | 1 | 1995 | 32 | 0.030 |
Why?
|
Adrenocorticotropic Hormone | 1 | 1995 | 159 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2015 | 2655 | 0.030 |
Why?
|
Fibroblasts | 1 | 2002 | 1652 | 0.030 |
Why?
|
Random Allocation | 1 | 1996 | 709 | 0.030 |
Why?
|
Fucosyltransferases | 1 | 2015 | 77 | 0.030 |
Why?
|
Oligonucleotides | 1 | 1996 | 229 | 0.030 |
Why?
|
Sequence Alignment | 1 | 1997 | 853 | 0.030 |
Why?
|
Poisson Distribution | 1 | 1995 | 92 | 0.030 |
Why?
|
E-Selectin | 1 | 2015 | 105 | 0.030 |
Why?
|
Blotting, Southern | 2 | 1992 | 405 | 0.030 |
Why?
|
Respiration, Artificial | 1 | 1998 | 584 | 0.030 |
Why?
|
Medical Oncology | 2 | 2017 | 1439 | 0.030 |
Why?
|
Withholding Treatment | 1 | 2016 | 163 | 0.030 |
Why?
|
Vasoconstrictor Agents | 1 | 1995 | 148 | 0.030 |
Why?
|
Cricetinae | 1 | 1996 | 709 | 0.030 |
Why?
|
P-Selectin | 1 | 2015 | 124 | 0.030 |
Why?
|
Thromboembolism | 1 | 2015 | 159 | 0.030 |
Why?
|
Actuarial Analysis | 3 | 1997 | 165 | 0.030 |
Why?
|
Phenotype | 4 | 2002 | 6316 | 0.030 |
Why?
|
Uracil-DNA Glycosidase | 1 | 1994 | 25 | 0.030 |
Why?
|
Monosomy | 1 | 2014 | 95 | 0.030 |
Why?
|
Cyanobacteria | 1 | 1994 | 21 | 0.030 |
Why?
|
Neoplasm Grading | 1 | 2019 | 1755 | 0.030 |
Why?
|
Seafood | 1 | 2014 | 9 | 0.030 |
Why?
|
Antibody-Producing Cells | 1 | 1973 | 15 | 0.030 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 1995 | 153 | 0.030 |
Why?
|
Macrophages | 5 | 1990 | 1332 | 0.030 |
Why?
|
Meningitis, Viral | 1 | 1994 | 13 | 0.030 |
Why?
|
RNA, Neoplasm | 4 | 1991 | 794 | 0.030 |
Why?
|
Hydrocortisone | 1 | 1995 | 390 | 0.030 |
Why?
|
Electrophoresis, Gel, Pulsed-Field | 1 | 2014 | 129 | 0.030 |
Why?
|
Podophyllotoxin | 2 | 1999 | 63 | 0.030 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2016 | 338 | 0.030 |
Why?
|
Serotyping | 1 | 2014 | 172 | 0.030 |
Why?
|
Leukemia, Promyelocytic, Acute | 3 | 1992 | 432 | 0.030 |
Why?
|
Mediastinal Neoplasms | 1 | 1998 | 421 | 0.030 |
Why?
|
Radiation Injuries | 1 | 2001 | 1431 | 0.030 |
Why?
|
Intubation, Intratracheal | 1 | 1998 | 450 | 0.030 |
Why?
|
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 1994 | 120 | 0.030 |
Why?
|
DNA, Fungal | 1 | 1994 | 129 | 0.030 |
Why?
|
Europe | 1 | 2015 | 654 | 0.030 |
Why?
|
Antibodies | 1 | 2016 | 845 | 0.030 |
Why?
|
Sensitivity and Specificity | 3 | 1997 | 5041 | 0.030 |
Why?
|
Monocytes | 2 | 1996 | 779 | 0.030 |
Why?
|
Gene Frequency | 1 | 1996 | 1178 | 0.030 |
Why?
|
Chromosomes, Human, Pair 17 | 2 | 1995 | 649 | 0.030 |
Why?
|
Meningitis, Bacterial | 1 | 1994 | 93 | 0.030 |
Why?
|
Isoenzymes | 2 | 1993 | 635 | 0.030 |
Why?
|
Critical Illness | 1 | 1998 | 725 | 0.030 |
Why?
|
Cell Nucleus | 3 | 1987 | 1642 | 0.030 |
Why?
|
Propensity Score | 1 | 2016 | 756 | 0.030 |
Why?
|
Mice, Inbred Strains | 4 | 1986 | 522 | 0.030 |
Why?
|
Candida albicans | 1 | 1994 | 182 | 0.030 |
Why?
|
RNA, Small Cytoplasmic | 1 | 1992 | 7 | 0.030 |
Why?
|
Peptides | 2 | 1996 | 1502 | 0.030 |
Why?
|
Microcomputers | 1 | 1992 | 38 | 0.030 |
Why?
|
Cardiac Pacing, Artificial | 1 | 1993 | 132 | 0.030 |
Why?
|
CD3 Complex | 2 | 2004 | 321 | 0.030 |
Why?
|
Community Health Planning | 1 | 2012 | 23 | 0.030 |
Why?
|
Antigens, Differentiation | 2 | 2008 | 248 | 0.030 |
Why?
|
Seminal Vesicles | 2 | 1983 | 155 | 0.030 |
Why?
|
Biopsy | 1 | 2020 | 3467 | 0.030 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 1992 | 165 | 0.030 |
Why?
|
Catalysis | 2 | 1983 | 251 | 0.030 |
Why?
|
Sheep | 2 | 1983 | 261 | 0.030 |
Why?
|
Leukemia, Myeloid, Accelerated Phase | 2 | 1999 | 115 | 0.030 |
Why?
|
Blood Component Transfusion | 1 | 1992 | 90 | 0.030 |
Why?
|
Opportunistic Infections | 1 | 1993 | 227 | 0.030 |
Why?
|
Sex Factors | 2 | 1995 | 2162 | 0.030 |
Why?
|
Leukocytosis | 1 | 1992 | 113 | 0.030 |
Why?
|
Histiocytosis, Non-Langerhans-Cell | 1 | 1991 | 25 | 0.030 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2015 | 393 | 0.030 |
Why?
|
Ribonucleoproteins | 1 | 1992 | 124 | 0.030 |
Why?
|
beta 2-Microglobulin | 1 | 1992 | 184 | 0.030 |
Why?
|
Histocytochemistry | 1 | 1992 | 187 | 0.030 |
Why?
|
Dexamethasone | 3 | 2009 | 1461 | 0.030 |
Why?
|
Iceland | 1 | 2011 | 12 | 0.030 |
Why?
|
Central Nervous System Neoplasms | 1 | 1996 | 511 | 0.030 |
Why?
|
Interleukin-2 | 1 | 1995 | 846 | 0.030 |
Why?
|
Finland | 1 | 2011 | 57 | 0.030 |
Why?
|
Norway | 1 | 2011 | 30 | 0.030 |
Why?
|
Denmark | 1 | 2011 | 49 | 0.020 |
Why?
|
APACHE | 1 | 2011 | 93 | 0.020 |
Why?
|
Mucositis | 1 | 2012 | 147 | 0.020 |
Why?
|
Drosophila | 1 | 1997 | 854 | 0.020 |
Why?
|
Leukemia P388 | 1 | 1991 | 25 | 0.020 |
Why?
|
Candidiasis | 1 | 1994 | 272 | 0.020 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 1992 | 230 | 0.020 |
Why?
|
L-Lactate Dehydrogenase | 3 | 2001 | 308 | 0.020 |
Why?
|
Radionuclide Imaging | 1 | 2012 | 659 | 0.020 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 1992 | 216 | 0.020 |
Why?
|
Leukemia L1210 | 1 | 1991 | 54 | 0.020 |
Why?
|
Blotting, Northern | 1 | 1992 | 698 | 0.020 |
Why?
|
Tyrosine | 1 | 1993 | 512 | 0.020 |
Why?
|
Oligodeoxyribonucleotides | 1 | 1992 | 261 | 0.020 |
Why?
|
Platelet Count | 1 | 1992 | 495 | 0.020 |
Why?
|
Logistic Models | 1 | 1998 | 3474 | 0.020 |
Why?
|
Gene Deletion | 1 | 1996 | 1466 | 0.020 |
Why?
|
Therapeutic Equivalency | 1 | 2010 | 50 | 0.020 |
Why?
|
Magnetics | 1 | 2011 | 109 | 0.020 |
Why?
|
Lymphoma, B-Cell | 1 | 1998 | 900 | 0.020 |
Why?
|
Influenza Vaccines | 1 | 2016 | 643 | 0.020 |
Why?
|
Autoantigens | 1 | 1992 | 237 | 0.020 |
Why?
|
Phosphotransferases | 1 | 1991 | 82 | 0.020 |
Why?
|
Dithiothreitol | 1 | 1990 | 21 | 0.020 |
Why?
|
Intention to Treat Analysis | 1 | 2010 | 132 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2014 | 549 | 0.020 |
Why?
|
Receptors, Immunologic | 1 | 1992 | 313 | 0.020 |
Why?
|
Transplantation | 1 | 2010 | 56 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2011 | 179 | 0.020 |
Why?
|
Transfection | 1 | 1996 | 2990 | 0.020 |
Why?
|
Introns | 1 | 1992 | 433 | 0.020 |
Why?
|
Vitamin B Deficiency | 1 | 1990 | 1 | 0.020 |
Why?
|
Hypoproteinemia | 1 | 1990 | 3 | 0.020 |
Why?
|
Pellagra | 1 | 1990 | 2 | 0.020 |
Why?
|
Vitamin K Deficiency | 1 | 1990 | 4 | 0.020 |
Why?
|
Isoantibodies | 2 | 2002 | 122 | 0.020 |
Why?
|
Riboflavin Deficiency | 1 | 1990 | 8 | 0.020 |
Why?
|
Radiation Dosage | 1 | 1995 | 1018 | 0.020 |
Why?
|
Tumor Stem Cell Assay | 2 | 1987 | 232 | 0.020 |
Why?
|
Catalase | 2 | 1981 | 71 | 0.020 |
Why?
|
Isoantigens | 1 | 1990 | 64 | 0.020 |
Why?
|
Transcription, Genetic | 2 | 1995 | 3158 | 0.020 |
Why?
|
Niacin | 1 | 1990 | 61 | 0.020 |
Why?
|
Thymine | 1 | 1990 | 46 | 0.020 |
Why?
|
Bacteremia | 1 | 1995 | 697 | 0.020 |
Why?
|
Folic Acid Deficiency | 1 | 1990 | 55 | 0.020 |
Why?
|
Bronchoalveolar Lavage | 1 | 2009 | 54 | 0.020 |
Why?
|
Epitopes | 1 | 1992 | 697 | 0.020 |
Why?
|
Hydroxylation | 2 | 1980 | 62 | 0.020 |
Why?
|
Peptide Fragments | 2 | 1992 | 1288 | 0.020 |
Why?
|
Multiple Organ Failure | 1 | 2011 | 182 | 0.020 |
Why?
|
Carbon Radioisotopes | 2 | 1986 | 118 | 0.020 |
Why?
|
Transduction, Genetic | 1 | 1991 | 474 | 0.020 |
Why?
|
Radiation Chimera | 3 | 1974 | 30 | 0.020 |
Why?
|
Lymphocyte Activation | 3 | 2006 | 1712 | 0.020 |
Why?
|
Anemia, Refractory, with Excess of Blasts | 2 | 2001 | 88 | 0.020 |
Why?
|
Blood Pressure | 1 | 1995 | 1491 | 0.020 |
Why?
|
Drug Costs | 1 | 2010 | 150 | 0.020 |
Why?
|
Triazoles | 1 | 1993 | 625 | 0.020 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2009 | 68 | 0.020 |
Why?
|
Benzylamines | 1 | 2009 | 103 | 0.020 |
Why?
|
Antigens, Surface | 1 | 1989 | 289 | 0.020 |
Why?
|
Breast Neoplasms | 4 | 2005 | 15899 | 0.020 |
Why?
|
Fiber Optic Technology | 1 | 2009 | 147 | 0.020 |
Why?
|
Heterocyclic Compounds | 1 | 2009 | 119 | 0.020 |
Why?
|
Proteins | 1 | 1997 | 1983 | 0.020 |
Why?
|
Models, Statistical | 1 | 1995 | 1180 | 0.020 |
Why?
|
Drug Evaluation | 2 | 1985 | 423 | 0.020 |
Why?
|
Graft vs Leukemia Effect | 1 | 2009 | 110 | 0.020 |
Why?
|
Cachexia | 1 | 1990 | 163 | 0.020 |
Why?
|
Cytochrome P-450 Enzyme System | 2 | 1980 | 210 | 0.020 |
Why?
|
Antibiotic Prophylaxis | 1 | 2009 | 184 | 0.020 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2007 | 138 | 0.020 |
Why?
|
Sialic Acid Binding Ig-like Lectin 3 | 1 | 2007 | 85 | 0.020 |
Why?
|
Chromosomes, Human | 1 | 1988 | 291 | 0.020 |
Why?
|
Chromatography, Liquid | 2 | 1979 | 350 | 0.020 |
Why?
|
Hospitals, University | 1 | 2008 | 214 | 0.020 |
Why?
|
Lymphotoxin-alpha | 1 | 1987 | 26 | 0.020 |
Why?
|
Naphthalimides | 1 | 1987 | 14 | 0.020 |
Why?
|
Electrophoresis, Agar Gel | 1 | 1987 | 83 | 0.020 |
Why?
|
Proto-Oncogenes | 1 | 1987 | 202 | 0.020 |
Why?
|
Camptothecin | 1 | 1990 | 526 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2005 | 1505 | 0.020 |
Why?
|
Cancer Care Facilities | 1 | 2012 | 894 | 0.020 |
Why?
|
Mathematics | 1 | 1987 | 136 | 0.020 |
Why?
|
Clinical Protocols | 2 | 1993 | 467 | 0.020 |
Why?
|
Chromosome Banding | 1 | 1987 | 259 | 0.020 |
Why?
|
Creatinine | 2 | 1996 | 539 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 1992 | 1585 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2012 | 1972 | 0.020 |
Why?
|
Ploidies | 1 | 1987 | 252 | 0.020 |
Why?
|
RNA | 1 | 1992 | 1024 | 0.020 |
Why?
|
Organophosphonates | 1 | 1987 | 64 | 0.020 |
Why?
|
Disease Progression | 3 | 2004 | 6772 | 0.020 |
Why?
|
Gene Expression Regulation | 2 | 1996 | 4066 | 0.020 |
Why?
|
Cell Nucleolus | 1 | 1986 | 92 | 0.020 |
Why?
|
Autopsy | 1 | 1986 | 176 | 0.020 |
Why?
|
Lymphocyte Culture Test, Mixed | 1 | 2006 | 92 | 0.020 |
Why?
|
Vinblastine | 1 | 1987 | 458 | 0.020 |
Why?
|
Leukemia, Monocytic, Acute | 1 | 1986 | 31 | 0.020 |
Why?
|
Spectrometry, Fluorescence | 1 | 1986 | 214 | 0.020 |
Why?
|
Cytotoxicity Tests, Immunologic | 3 | 1975 | 89 | 0.020 |
Why?
|
Infusions, Parenteral | 1 | 1986 | 192 | 0.020 |
Why?
|
Skin Diseases | 1 | 1989 | 354 | 0.020 |
Why?
|
Protein Binding | 2 | 1983 | 3470 | 0.020 |
Why?
|
Dimethadione | 1 | 1985 | 2 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2010 | 755 | 0.020 |
Why?
|
Onium Compounds | 1 | 1985 | 9 | 0.020 |
Why?
|
DNA Probes | 2 | 2000 | 219 | 0.020 |
Why?
|
Immunoglobulin Light Chains | 1 | 1986 | 109 | 0.020 |
Why?
|
Trityl Compounds | 1 | 1985 | 3 | 0.020 |
Why?
|
Pulmonary Edema | 1 | 1985 | 77 | 0.020 |
Why?
|
Phosphopyruvate Hydratase | 1 | 2005 | 88 | 0.020 |
Why?
|
K562 Cells | 1 | 2006 | 344 | 0.020 |
Why?
|
Cell Fractionation | 1 | 1985 | 68 | 0.020 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2005 | 150 | 0.020 |
Why?
|
Diploidy | 1 | 1995 | 112 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2011 | 1318 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 1998 | 2571 | 0.020 |
Why?
|
Mouth Mucosa | 1 | 2005 | 217 | 0.020 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 1990 | 879 | 0.020 |
Why?
|
Surveys and Questionnaires | 1 | 2017 | 5750 | 0.020 |
Why?
|
Nucleotidases | 2 | 1981 | 13 | 0.020 |
Why?
|
Neoadjuvant Therapy | 2 | 2013 | 5012 | 0.020 |
Why?
|
Iron Radioisotopes | 2 | 1974 | 5 | 0.020 |
Why?
|
Phorbols | 1 | 1984 | 9 | 0.020 |
Why?
|
Adenosine Deaminase | 2 | 1981 | 95 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2013 | 4938 | 0.010 |
Why?
|
Glycolysis | 1 | 1987 | 527 | 0.010 |
Why?
|
Anemia, Aplastic | 1 | 2005 | 230 | 0.010 |
Why?
|
Autoradiography | 2 | 1986 | 131 | 0.010 |
Why?
|
Tritium | 2 | 1986 | 206 | 0.010 |
Why?
|
Structure-Activity Relationship | 2 | 1986 | 962 | 0.010 |
Why?
|
Steroids | 1 | 2005 | 359 | 0.010 |
Why?
|
Receptors, Complement | 1 | 1984 | 49 | 0.010 |
Why?
|
Asparaginase | 1 | 1984 | 185 | 0.010 |
Why?
|
Carrier Proteins | 1 | 1992 | 2062 | 0.010 |
Why?
|
Intestinal Mucosa | 1 | 1990 | 1102 | 0.010 |
Why?
|
Eye | 1 | 2005 | 304 | 0.010 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 1984 | 227 | 0.010 |
Why?
|
Leucovorin | 1 | 1984 | 333 | 0.010 |
Why?
|
Dasatinib | 1 | 2007 | 862 | 0.010 |
Why?
|
Adenine | 1 | 1987 | 643 | 0.010 |
Why?
|
Ultraviolet Rays | 1 | 2006 | 587 | 0.010 |
Why?
|
Chemical and Drug Induced Liver Injury | 1 | 1995 | 190 | 0.010 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 1 | 2004 | 170 | 0.010 |
Why?
|
Hyperlipidemias | 1 | 2005 | 237 | 0.010 |
Why?
|
Amino Acid Sequence | 3 | 1999 | 4292 | 0.010 |
Why?
|
Naphthacenes | 1 | 1983 | 4 | 0.010 |
Why?
|
Mitochondrial Swelling | 1 | 1983 | 13 | 0.010 |
Why?
|
Genome, Plant | 1 | 2003 | 27 | 0.010 |
Why?
|
Glycoproteins | 1 | 1987 | 758 | 0.010 |
Why?
|
Fixatives | 1 | 1983 | 30 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2006 | 11664 | 0.010 |
Why?
|
Cortisone | 2 | 1973 | 19 | 0.010 |
Why?
|
Histocompatibility Antigens Class II | 1 | 1984 | 186 | 0.010 |
Why?
|
Iron Isotopes | 2 | 1973 | 3 | 0.010 |
Why?
|
Receptors, Glucocorticoid | 2 | 1981 | 194 | 0.010 |
Why?
|
Histological Techniques | 1 | 1983 | 65 | 0.010 |
Why?
|
Lewis X Antigen | 1 | 2002 | 47 | 0.010 |
Why?
|
Cytotoxicity, Immunologic | 2 | 1982 | 680 | 0.010 |
Why?
|
Antibodies, Monoclonal, Humanized | 2 | 2007 | 3308 | 0.010 |
Why?
|
Time | 1 | 2003 | 182 | 0.010 |
Why?
|
Gene Amplification | 1 | 1986 | 741 | 0.010 |
Why?
|
Chromosome Segregation | 1 | 2003 | 83 | 0.010 |
Why?
|
Microsomes, Liver | 1 | 1983 | 117 | 0.010 |
Why?
|
CD56 Antigen | 1 | 2002 | 85 | 0.010 |
Why?
|
Barium | 1 | 1982 | 26 | 0.010 |
Why?
|
Disease Models, Animal | 2 | 1994 | 7295 | 0.010 |
Why?
|
Receptors, Antigen, B-Cell | 1 | 1984 | 171 | 0.010 |
Why?
|
Kidney Medulla | 1 | 1982 | 43 | 0.010 |
Why?
|
Lymph Nodes | 4 | 1974 | 2996 | 0.010 |
Why?
|
Microsomes | 1 | 1982 | 67 | 0.010 |
Why?
|
Anemia, Sickle Cell | 1 | 2005 | 345 | 0.010 |
Why?
|
Tissue Distribution | 2 | 1986 | 903 | 0.010 |
Why?
|
Methyldopa | 1 | 1981 | 5 | 0.010 |
Why?
|
Nucleoside Deaminases | 1 | 1981 | 36 | 0.010 |
Why?
|
Angiogenesis Inhibitors | 1 | 2009 | 1257 | 0.010 |
Why?
|
DNA Replication | 1 | 1986 | 748 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2006 | 1232 | 0.010 |
Why?
|
DNA Nucleotidyltransferases | 1 | 1981 | 31 | 0.010 |
Why?
|
Thymus Gland | 2 | 1973 | 297 | 0.010 |
Why?
|
Biomarkers | 1 | 1993 | 5082 | 0.010 |
Why?
|
Chimera | 2 | 1993 | 147 | 0.010 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2006 | 611 | 0.010 |
Why?
|
Islets of Langerhans | 1 | 1982 | 233 | 0.010 |
Why?
|
Itraconazole | 1 | 2001 | 77 | 0.010 |
Why?
|
Immunocompromised Host | 2 | 1997 | 702 | 0.010 |
Why?
|
Pregnancy | 1 | 2014 | 7609 | 0.010 |
Why?
|
Survivors | 1 | 2006 | 1032 | 0.010 |
Why?
|
Chromosome Walking | 1 | 2000 | 4 | 0.010 |
Why?
|
Leukemia, Myeloid, Chronic-Phase | 1 | 1995 | 510 | 0.010 |
Why?
|
Respiratory Function Tests | 1 | 2001 | 323 | 0.010 |
Why?
|
Patient Care Team | 1 | 2006 | 798 | 0.010 |
Why?
|
Stimulation, Chemical | 1 | 1979 | 97 | 0.010 |
Why?
|
Genes, MHC Class II | 1 | 2000 | 68 | 0.010 |
Why?
|
Chromosome Disorders | 2 | 1995 | 417 | 0.010 |
Why?
|
Skin | 1 | 2005 | 1274 | 0.010 |
Why?
|
DNA Adducts | 1 | 1981 | 214 | 0.010 |
Why?
|
Muramidase | 1 | 1980 | 108 | 0.010 |
Why?
|
Kidney | 2 | 1997 | 2167 | 0.010 |
Why?
|
Immunosorbent Techniques | 1 | 1979 | 58 | 0.010 |
Why?
|
Receptors, Steroid | 1 | 1981 | 291 | 0.010 |
Why?
|
Methylprednisolone Hemisuccinate | 1 | 1999 | 16 | 0.010 |
Why?
|
Radiation Pneumonitis | 1 | 2001 | 303 | 0.010 |
Why?
|
Receptor, Angiotensin, Type 1 | 1 | 1999 | 81 | 0.010 |
Why?
|
Antibody Specificity | 2 | 1980 | 337 | 0.010 |
Why?
|
Receptor, Angiotensin, Type 2 | 1 | 1999 | 46 | 0.010 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 1979 | 100 | 0.010 |
Why?
|
Phytohemagglutinins | 1 | 1999 | 70 | 0.010 |
Why?
|
Methods | 1 | 1979 | 190 | 0.010 |
Why?
|
Whole-Body Counting | 1 | 1979 | 27 | 0.010 |
Why?
|
Antibodies, Neoplasm | 1 | 1980 | 263 | 0.010 |
Why?
|
Aldehyde Oxidoreductases | 1 | 1978 | 34 | 0.010 |
Why?
|
Glutathione Peroxidase | 1 | 1978 | 62 | 0.010 |
Why?
|
Oxidoreductases, N-Demethylating | 1 | 1978 | 41 | 0.010 |
Why?
|
Cardiac Output | 1 | 1999 | 195 | 0.010 |
Why?
|
Alkaline Phosphatase | 2 | 1996 | 209 | 0.010 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 1999 | 146 | 0.010 |
Why?
|
Phenolphthaleins | 1 | 1978 | 2 | 0.010 |
Why?
|
Uridine Diphosphate | 1 | 1978 | 8 | 0.010 |
Why?
|
Hymecromone | 1 | 1978 | 6 | 0.010 |
Why?
|
Glucuronates | 1 | 1978 | 12 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2000 | 761 | 0.010 |
Why?
|
Lactates | 1 | 1978 | 114 | 0.010 |
Why?
|
Naphthols | 1 | 1978 | 25 | 0.010 |
Why?
|
Serology | 1 | 1997 | 5 | 0.010 |
Why?
|
ADP-ribosyl Cyclase | 1 | 1996 | 33 | 0.010 |
Why?
|
Thy-1 Antigens | 1 | 1996 | 48 | 0.010 |
Why?
|
Telomere | 1 | 2000 | 522 | 0.010 |
Why?
|
Nucleic Acid Hybridization | 2 | 1988 | 539 | 0.010 |
Why?
|
Cysteine | 1 | 1977 | 215 | 0.010 |
Why?
|
ADP-ribosyl Cyclase 1 | 1 | 1996 | 141 | 0.010 |
Why?
|
Insulin | 1 | 1982 | 1465 | 0.010 |
Why?
|
Bone Marrow Diseases | 1 | 1997 | 185 | 0.010 |
Why?
|
Moloney murine leukemia virus | 1 | 1975 | 24 | 0.010 |
Why?
|
Lymphocyte Count | 1 | 1997 | 490 | 0.010 |
Why?
|
Vomiting | 1 | 1997 | 351 | 0.010 |
Why?
|
DNA Transposable Elements | 1 | 1997 | 225 | 0.010 |
Why?
|
Immunity, Innate | 1 | 1980 | 692 | 0.010 |
Why?
|
Polymorphism, Single-Stranded Conformational | 1 | 1995 | 180 | 0.010 |
Why?
|
Arteriosclerosis | 1 | 1996 | 181 | 0.010 |
Why?
|
Nausea | 1 | 1997 | 528 | 0.010 |
Why?
|
Fluorouracil | 1 | 2000 | 1954 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1997 | 1010 | 0.010 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 1995 | 239 | 0.010 |
Why?
|
Karnofsky Performance Status | 1 | 1995 | 177 | 0.010 |
Why?
|
Pedigree | 1 | 1999 | 1914 | 0.010 |
Why?
|
Hemoglobins | 1 | 1996 | 477 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2000 | 2251 | 0.010 |
Why?
|
Membranes | 1 | 1994 | 33 | 0.010 |
Why?
|
Iodine Radioisotopes | 1 | 1996 | 383 | 0.010 |
Why?
|
Immunoglobulin M | 1 | 1975 | 348 | 0.010 |
Why?
|
Centrifugation, Density Gradient | 1 | 1994 | 124 | 0.010 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2000 | 2242 | 0.010 |
Why?
|
Spectrophotometry | 1 | 1994 | 83 | 0.010 |
Why?
|
Immunomagnetic Separation | 1 | 1994 | 43 | 0.010 |
Why?
|
Chromium Radioisotopes | 1 | 1973 | 9 | 0.010 |
Why?
|
Hemagglutination Tests | 1 | 1973 | 33 | 0.010 |
Why?
|
Electron Transport Complex IV | 1 | 1994 | 57 | 0.010 |
Why?
|
Glass | 1 | 1973 | 30 | 0.010 |
Why?
|
Premedication | 1 | 1994 | 135 | 0.010 |
Why?
|
Dextrans | 1 | 1994 | 91 | 0.010 |
Why?
|
Immune Sera | 1 | 1973 | 147 | 0.010 |
Why?
|
Radiation Effects | 1 | 1973 | 20 | 0.010 |
Why?
|
Regression Analysis | 1 | 1997 | 1556 | 0.010 |
Why?
|
Adsorption | 1 | 1973 | 46 | 0.010 |
Why?
|
Remission, Spontaneous | 1 | 1993 | 122 | 0.010 |
Why?
|
Free Radicals | 2 | 1985 | 63 | 0.010 |
Why?
|
Cross Reactions | 1 | 1974 | 270 | 0.010 |
Why?
|
Bone Marrow Examination | 1 | 1993 | 153 | 0.010 |
Why?
|
Interferons | 2 | 1987 | 295 | 0.010 |
Why?
|
Chickens | 1 | 1973 | 527 | 0.010 |
Why?
|
Immunization, Passive | 1 | 1973 | 171 | 0.010 |
Why?
|
Lymphoid Tissue | 1 | 1973 | 95 | 0.010 |
Why?
|
Peptide Mapping | 1 | 1993 | 114 | 0.010 |
Why?
|
Nitriles | 1 | 1977 | 922 | 0.010 |
Why?
|
Nucleic Acid Denaturation | 1 | 1992 | 35 | 0.010 |
Why?
|
Injections, Subcutaneous | 1 | 1993 | 344 | 0.010 |
Why?
|
CD2 Antigens | 1 | 1992 | 31 | 0.010 |
Why?
|
Precipitin Tests | 1 | 1993 | 336 | 0.010 |
Why?
|
Blood Cells | 1 | 1993 | 128 | 0.010 |
Why?
|
Mice, Inbred BALB C | 2 | 1994 | 2382 | 0.010 |
Why?
|
Glycosylation | 1 | 1993 | 215 | 0.010 |
Why?
|
Autoimmune Diseases | 1 | 1996 | 410 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 1989 | 4706 | 0.010 |
Why?
|
Immunization | 1 | 1974 | 403 | 0.010 |
Why?
|
Connective Tissue Diseases | 1 | 1992 | 51 | 0.010 |
Why?
|
Luminescent Measurements | 1 | 1992 | 150 | 0.010 |
Why?
|
Lymphoma, Follicular | 1 | 1997 | 595 | 0.010 |
Why?
|
Benz(a)Anthracenes | 1 | 1971 | 9 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2000 | 3922 | 0.010 |
Why?
|
Radiography | 1 | 1996 | 1925 | 0.010 |
Why?
|
Membrane Glycoproteins | 1 | 1996 | 1094 | 0.010 |
Why?
|
Photography | 1 | 1992 | 142 | 0.010 |
Why?
|
Kanamycin Kinase | 1 | 1991 | 16 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 1993 | 1056 | 0.010 |
Why?
|
Organ Transplantation | 1 | 1994 | 197 | 0.010 |
Why?
|
Neomycin | 1 | 1991 | 38 | 0.010 |
Why?
|
Vaccination | 1 | 1997 | 1138 | 0.010 |
Why?
|
Receptors, Retinoic Acid | 1 | 1992 | 368 | 0.010 |
Why?
|
Temperature | 1 | 1992 | 515 | 0.010 |
Why?
|
Interleukin-1beta | 1 | 1992 | 301 | 0.010 |
Why?
|
Mice, Inbred CBA | 2 | 1984 | 77 | 0.010 |
Why?
|
5'-Nucleotidase | 2 | 1981 | 62 | 0.010 |
Why?
|
Lymphatic Metastasis | 1 | 2000 | 4883 | 0.010 |
Why?
|
Drug Resistance, Microbial | 1 | 1991 | 217 | 0.010 |
Why?
|
Pulmonary Fibrosis | 1 | 1991 | 172 | 0.010 |
Why?
|
Topoisomerase II Inhibitors | 1 | 1990 | 57 | 0.010 |
Why?
|
Gene Rearrangement, T-Lymphocyte | 1 | 1989 | 68 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 2 | 1988 | 1072 | 0.010 |
Why?
|
X-Ray Intensifying Screens | 1 | 1989 | 33 | 0.010 |
Why?
|
Software | 1 | 1997 | 1330 | 0.010 |
Why?
|
Thoracic Diseases | 1 | 1989 | 32 | 0.010 |
Why?
|
Tretinoin | 1 | 1992 | 631 | 0.010 |
Why?
|
Topoisomerase I Inhibitors | 1 | 1990 | 77 | 0.010 |
Why?
|
Urticaria Pigmentosa | 1 | 1989 | 2 | 0.010 |
Why?
|
False Negative Reactions | 1 | 1989 | 282 | 0.010 |
Why?
|
Ecchymosis | 1 | 1989 | 20 | 0.010 |
Why?
|
Quality of Life | 1 | 2003 | 4611 | 0.010 |
Why?
|
Mice, SCID | 1 | 1993 | 1872 | 0.010 |
Why?
|
False Positive Reactions | 1 | 1989 | 358 | 0.010 |
Why?
|
Hemin | 1 | 1988 | 24 | 0.010 |
Why?
|
Purpura | 1 | 1989 | 31 | 0.010 |
Why?
|
Vasculitis | 1 | 1989 | 68 | 0.010 |
Why?
|
Autoantibodies | 1 | 1992 | 588 | 0.010 |
Why?
|
Immunotherapy | 1 | 1982 | 3395 | 0.000 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 1992 | 688 | 0.000 |
Why?
|
Crithidia | 1 | 1987 | 1 | 0.000 |
Why?
|
Malates | 1 | 1987 | 7 | 0.000 |
Why?
|
Pyruvates | 1 | 1987 | 29 | 0.000 |
Why?
|
Complement System Proteins | 2 | 1980 | 137 | 0.000 |
Why?
|
Proton-Translocating ATPases | 1 | 1987 | 28 | 0.000 |
Why?
|
Aneuploidy | 1 | 1988 | 372 | 0.000 |
Why?
|
Electron Transport | 1 | 1987 | 83 | 0.000 |
Why?
|
Citrates | 1 | 1987 | 39 | 0.000 |
Why?
|
Immunoblotting | 1 | 1989 | 900 | 0.000 |
Why?
|
Aspartic Acid | 1 | 1987 | 127 | 0.000 |
Why?
|
Glutamates | 1 | 1987 | 131 | 0.000 |
Why?
|
Growth Inhibitors | 1 | 1987 | 154 | 0.000 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 1987 | 202 | 0.000 |
Why?
|
Superoxides | 1 | 1987 | 216 | 0.000 |
Why?
|
Dactinomycin | 1 | 1986 | 143 | 0.000 |
Why?
|
Immunoenzyme Techniques | 1 | 1988 | 1183 | 0.000 |
Why?
|
Phosphates | 1 | 1987 | 190 | 0.000 |
Why?
|
Models, Biological | 2 | 1988 | 3258 | 0.000 |
Why?
|
Thymidine | 1 | 1986 | 152 | 0.000 |
Why?
|
Oxidative Phosphorylation | 1 | 1987 | 255 | 0.000 |
Why?
|
Arabinofuranosylcytosine Triphosphate | 1 | 1985 | 75 | 0.000 |
Why?
|
Endoplasmic Reticulum | 1 | 1987 | 317 | 0.000 |
Why?
|
Horseradish Peroxidase | 1 | 1985 | 18 | 0.000 |
Why?
|
Electron Spin Resonance Spectroscopy | 1 | 1985 | 62 | 0.000 |
Why?
|
Chromatography, Thin Layer | 1 | 1985 | 69 | 0.000 |
Why?
|
Regeneration | 1 | 1988 | 281 | 0.000 |
Why?
|
Gene Rearrangement | 1 | 1989 | 787 | 0.000 |
Why?
|
Mice, Inbred A | 1 | 1984 | 31 | 0.000 |
Why?
|
Macrophage-1 Antigen | 1 | 1984 | 54 | 0.000 |
Why?
|
Interphase | 1 | 1984 | 146 | 0.000 |
Why?
|
Receptors, Cell Surface | 1 | 1987 | 878 | 0.000 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 1982 | 182 | 0.000 |
Why?
|
Mice, Obese | 1 | 1982 | 104 | 0.000 |
Why?
|
Mass Spectrometry | 1 | 1985 | 709 | 0.000 |
Why?
|
Binding, Competitive | 1 | 1982 | 302 | 0.000 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 1985 | 630 | 0.000 |
Why?
|
Enzyme Inhibitors | 1 | 1990 | 1945 | 0.000 |
Why?
|
Mycobacterium bovis | 1 | 1982 | 67 | 0.000 |
Why?
|
Cyclic AMP | 1 | 1982 | 368 | 0.000 |
Why?
|
Clinical Enzyme Tests | 1 | 1980 | 26 | 0.000 |
Why?
|
Guinea Pigs | 1 | 1980 | 244 | 0.000 |
Why?
|
DNA Nucleotidylexotransferase | 1 | 1980 | 57 | 0.000 |
Why?
|
Diagnosis, Differential | 1 | 1989 | 4793 | 0.000 |
Why?
|
Formates | 1 | 1978 | 13 | 0.000 |
Why?
|
Phenobarbital | 1 | 1978 | 49 | 0.000 |
Why?
|
Chromatography, Gas | 1 | 1978 | 40 | 0.000 |
Why?
|
Formaldehyde | 1 | 1978 | 115 | 0.000 |
Why?
|
Glucose | 1 | 1982 | 1262 | 0.000 |
Why?
|
Animals, Newborn | 1 | 1980 | 1346 | 0.000 |
Why?
|
Mice, Inbred C57BL | 1 | 1986 | 7069 | 0.000 |
Why?
|
Culture Techniques | 1 | 1971 | 132 | 0.000 |
Why?
|
Antibody Formation | 1 | 1971 | 386 | 0.000 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 1971 | 499 | 0.000 |
Why?
|